var title_f36_22_37216="Tissue core Gross";
var content_f36_22_37216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Tissue core",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Picture of a tissue core (arrow) obtained by a trucut biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37216=[""].join("\n");
var outline_f36_22_37216=null;
var title_f36_22_37217="Injection at mid trochanter";
var content_f36_22_37217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Injection at the mid-trochanteric process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A local anesthetic block placed below the gluteus medius tendon at the periosteum of the trochanteric process can confirm the presence of trochanteric bursitis. The patient is placed in the lateral decubitus position with the affected side up and the knees flexed to 90&ordm;. The superior, posterior, and anterior edges of the trochanteric process are palpated and marked. The point of entry is directly over the center point of the trochanter, approximately 4 cm (1.5 in)&nbsp;below the superior trochanter. Alternatively, the point of entry is at the crown of the trochanter viewed tangentially. Topical anesthetic (eg, ethyl chloride) is&nbsp;applied to&nbsp;the skin. Local anesthetic is&nbsp;injected at the gluteus medius tissue plane (1 mL) and at the periosteum of the femur (0.5 to 1 mL). A 4 cm (1.5 in), 22-gauge or 22-gauge spinal needle is inserted perpendicular to the skin; the depth is 4 to&nbsp;7.5 cm (1.5 to 3 in)&nbsp;to the femur. The needle is held lightly and advanced through the low resistance of the subcutaneous fat to the firm, rubbery resistance of the gluteus medius tissue plane. Following anesthesia at this level, the needle is advanced with firm pressure approximately 1.3 cm (0.5 in)&nbsp;farther to the periosteum of the femur. The patient will usually experience sharp pain as the needle touches the periosteum. Injection at this deeper level requires firm pressure. The needle should be rotated 180&ordm; or withdrawn slightly if excessive pressure is encountered. If the trochanter tenderness is significantly relieved with anesthetic injection, 1 mL of triamcinolone acetonide 40 mg/mL can be injected through the same needle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37217=[""].join("\n");
var outline_f36_22_37217=null;
var title_f36_22_37218="Pisiform fractures";
var content_f36_22_37218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pisiform fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37218/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37218/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37218/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37218/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37218/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/22/37218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity fractures are among the most common of the extremity injuries with carpal fractures accounting for 18 percent of hand fractures and 6 percent of all fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37218/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Of these, fractures to bones of the proximal row are most frequent. Fractures of the pisiform bone occur less often than fractures of the scaphoid, lunate, or triquetrum. Pisiform fractures account for 1 to 3 percent of all carpal bone osseous injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37218/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], with an estimated incidence from 1 in 100 to 1 in 460 of all carpal fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37218/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews fractures of the pisiform in adults. An overview of carpal fractures in adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pisiform is a sesamoid bone within the flexor carpi ulnaris tendon (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"mobipreview.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    ). Ossification occurs between 7 and 10 years of age, and is complete by age 12. It is the last carpus to completely ossify. Segmentation may be present before age 12 and should not be confused with fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37218/abstract/5\">",
"     5",
"    </a>",
"    ]. It is easily palpable on the volar surface of the wrist directly proximal to the fifth phalanx at the distal wrist crease. There are ligamentous attachments to the triquetrum, hamate and fifth metacarpal. The pisiform marks the ulnar border of Guyon&rsquo;s canal. With pisiform fracture there can be concomitant injury to the ulnar nerve, which traverses the canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most commonly the pisiform is injured in a fall on the outstretched hand with the wrist in extension or if the heel of the hand is used like a hammer to strike an object. When the wrist is in this position, the flexor carpi ulnaris tendon compresses the pisiform to the triquetrum. These mechanisms can create an avulsion fracture of the distal aspect of the pisiform, a linear fracture, or a chondral injury to its dorsal surface. The pisiform serves as an anchor for several ligamentous attachments, and is the origin of the abductor digiti minimi, and thus there is a 50 percent chance of an associated injury to the distal radius or to another carpal bone when a fracture of the pisiform is identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37218/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients present with pain and swelling at the palmar and ulnar aspects of the wrist. Tenderness is present directly over the pisiform and over the hypothenar eminence. Typically, there is no loss of motion in the wrist and no deformity is seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89394965\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for pisiform fracture includes: hamate fracture, carpal ligamentous disruption, pisotriquetral chondromalacia, osteoarthritis, and with delayed presentation tendonitis of the flexor carpi ulnaris. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9620?source=see_link\">",
"     \"Hamate fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard wrist radiographs (AP, lateral and oblique views) can be obtained to rule out other carpal injury (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83269 \" href=\"mobipreview.htm?14/22/14691\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85830 \" href=\"mobipreview.htm?8/19/8499\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"mobipreview.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    ). The PA may show a longitudinal (sagittal), transverse, or comminuted fracture. If not visible on standard films, the pisiform can be visualized with a carpal tunnel view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81015 \" href=\"mobipreview.htm?0/60/960\">",
"     image 4",
"    </a>",
"    ), or a lateral wrist view obtained with 20 to 30 degrees of supination. If the fracture is not visible and clinical suspicion is high, CT scan is obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pisiform fractures generally heal well with casting. A widely displaced fracture associated with decreased flexor carpi ulnaris function in an athlete desiring a quick return to play is best treated with resection of the pisiform, and surgical referral is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37218/abstract/6\">",
"     6",
"    </a>",
"    ]. If symptomatic nonunion or malunion develop after appropriate care, or if there is symptomatic post-traumatic arthrosis of the pisiform-triquetral joint, referral for surgical excision is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If swelling is marked, these fractures can be treated initially with a volar (",
"    <a class=\"graphic graphic_figure graphicRef65696 \" href=\"mobipreview.htm?42/15/43263\">",
"     figure 1",
"    </a>",
"    ) or dorsal splint. If swelling is limited, definitive immobilization using a short arm cast is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pisiform fractures heal well with three to six weeks of immobilization in a short arm cast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37218/abstract/2-4,7\">",
"     2-4,7",
"    </a>",
"    ]. Malunions and non-unions do occur, but are rare. Posttraumatic arthrosis may be a late sequela [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37218/abstract/1\">",
"     1",
"    </a>",
"    ]. Fortunately, all three of these problems can be cured with excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activities, including sports can be resumed with cast protection as soon as the acute pain subsides. In the rare case of a non-union, an athlete can be protected until excision can be performed at the end of a season.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pisiform fractures are uncommon, and are usually non-displaced.",
"     </li>",
"     <li>",
"      A common finding is pain to palpation directly over the pisiform, which is relatively superficial and located proximal to the fifth digit at the distal palmar crease.",
"     </li>",
"     <li>",
"      If not seen on standard radiographs, the pisiform can be visualized with a carpal tunnel view or a lateral wrist with 20 degrees of supination. CT scan can be used if plain x-ray is not diagnostic.",
"     </li>",
"     <li>",
"      Pisiform fractures generally heal well with three to six weeks of immobilization in a short arm cast. In athletes desiring a quick return to play, or in cases where complications arise or are likely to arise, it is best to obtain referral to a hand surgeon.",
"     </li>",
"     <li>",
"      Malunion or non-unions as well as post-traumatic arthrosis are possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15664126\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dobyns JH, Beckenbaugh RD, Bryan RS, et al. Fractures of the hand and wrist. In: Hand Surgery, 3rd, Flynn JE (Ed), Williams &amp; Wilkins, Philadelphia 1982.",
"    </li>",
"    <li>",
"     Eiff MP, Hatch RL. Chapter 5: Carpal fractures. In: Fracture Management for Primary Care, 3rd, Saunders, Philadelphia 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37218/abstract/3\">",
"      Geissler WB. Carpal fractures in athletes. Clin Sports Med 2001; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     Seitz WH Jr, Papandrea RF. Fractures and dislocations of the wrist. In: Rockwood and Green's Fractures in Adults, 5th, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37218/abstract/5\">",
"      Fleege MA, Jebson PJ, Renfrew DL, et al. Pisiform fractures. Skeletal Radiol 1991; 20:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37218/abstract/6\">",
"      Marchessault J, Conti M, Baratz ME. Carpal fractures in athletes excluding the scaphoid. Hand Clin 2009; 25:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37218/abstract/7\">",
"      Rettig ME, Dassa GL, Raskin KB, Melone CP Jr. Wrist fractures in the athlete. Distal radius and carpal fractures. Clin Sports Med 1998; 17:469.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 200 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37218=[""].join("\n");
var outline_f36_22_37218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89394965\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15664126\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/200|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/16/38146\" title=\"diagnostic image 1\">",
"      Normal adult wrist AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/22/14691\" title=\"diagnostic image 2\">",
"      Gilula lines wrist radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/19/8499\" title=\"diagnostic image 3\">",
"      Normal wrist x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/60/960\" title=\"diagnostic image 4\">",
"      Carpal tunnel view of the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/200|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/15/43263\" title=\"figure 1\">",
"      Volar forearm splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9620?source=related_link\">",
"      Hamate fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_22_37219="APL bone marrow aspirate III";
var content_f36_22_37219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Bone marrow aspirate from a patient with acute promyelocytic leukemia (APL)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that some of the abnormal promyelocytes have abundant Auer rods filling the cytoplasm. These cells have been termed &ldquo;faggot cells&rdquo; after the Old English term, &ldquo;faggot&rdquo;, meaning a bundle of sticks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37219=[""].join("\n");
var outline_f36_22_37219=null;
var title_f36_22_37220="ECG tutorial: Electrical components of the ECG";
var content_f36_22_37220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Electrical components of the ECG",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37220/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37220/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37220/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37220/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37220/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37220/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/22/37220/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram provides a graphic record of the electrical activity of the heart. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/262?source=see_link\">",
"     \"Basic principles of electrocardiographic interpretation\"",
"    </a>",
"    .) Each cardiac cell generates an action potential as it becomes depolarized and then repolarized during a normal cycle (",
"    <a class=\"graphic graphic_movie graphicRef61058 \" href=\"mobipreview.htm?31/46/32481\">",
"     movie 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depolarization of cardiac cells proceeds in an orderly fashion in the normal situation beginning in the sinus node, and then spreading sequentially through the atria, AV node, and ventricles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9283?source=see_link\">",
"     \"ECG tutorial: Physiology of the conduction system\"",
"    </a>",
"    .) The electrical signal spreads through the heart as a wavefront(s) of depolarization. This wavefront(s) results in a minute electrical field that can be detected at the body's surface as an electrocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6614?source=see_link\">",
"     \"Anatomy and electrophysiology of the sinoatrial node\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22038?source=see_link\">",
"     \"ECG tutorial: Intraventricular block\"",
"    </a>",
"    .) In particular, the surface ECG records the activation and recovery signals of working myocardial cells, not of the pacemaker cells of the SA and VA nodes, or of the specialized conduction system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELECTRICAL FIELDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All electrical fields have two important associated parameters, magnitude and direction. The standard electrocardiogram is simply a graphical representation of the direction and magnitude of the electrical field of the heart as it changes with time; each lead &ldquo;looks at&rdquo; this electrical field from a different angle.",
"   </p>",
"   <p>",
"    One can imagine, for example, a strip of cardiac muscle that is being stimulated by an external source. Initially the inside of the cell is negative while the outside is relatively positive. When the muscle is stimulated and sodium ions flow into the cell, the outside becomes negative with reference to the inside of the cell (which is now positive). However, the section of the myocardial membrane that has not yet become depolarized (or is in a resting state) remains positive. Thus, this sequence establishes a dipole that has direction and magnitude (",
"    <a class=\"graphic graphic_figure graphicRef53973 \" href=\"mobipreview.htm?19/1/19486\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The direction of the dipole is simply the net direction of the positive charge relative to the negative charge; this corresponds to the direction of the wavefront of depolarization for the muscle strip. The magnitude of the dipole is determined by the amount of positive sodium ions that flow into the cell (eg, how positive the inside of the cell becomes). Since the heart is a complex three dimensional structure consisting of millions of cells, the direction of the dipole changes with time and is the result of a summation of all the instantaneous dipoles. At any point in time, the mean dipole can be determined. This changing direction of the electrical impulse is the basis of vectorcardiography.",
"   </p>",
"   <p>",
"    The mean direction of the electrical field during the entire cardiac cycle is called the electrical axis. The magnitude of the electrical field as measured by two leads is proportional to the distance between the electrodes and the dipole, the orientation of the electrodes to the dipole, and to the size of the dipole. On the surface ECG, the distance between the electrodes and dipole may be influenced by chest wall shape, presence of thoracic obesity, subcutaneous edema, pulmonary emphysema, pericardial effusion, or other factors. The size of the dipole is predominantly related to the mass of tissue being depolarized.",
"   </p>",
"   <p>",
"    Three pairs of electrodes placed along the muscle strip will record different electric:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first pair of electrodes are located at the site of origin of depolarization. The electrical signal moves away from the origin at the start of depolarization; thus, a strong negative charge is recorded. The electrode continually sees a negative charge throughout depolarization of the strip since the dipole is constantly moving away from it until depolarization of the muscle strip is completed, there is no further movement of an electrical charge, and an isoelectric baseline is restored.",
"     </li>",
"     <li>",
"      The second pair of electrodes records a dipole as seen from the middle of the muscle strip. During the first half of depolarization, there is a positive electrical signal moving toward it; thus a continually growing upward deflection is recorded. When the dipole passes the electrode, however, there is a sudden change from a positive to a negative deflection since the electric charge is now moving away from the electrode. This deflection is at its most negative magnitude immediately after the dipole passes beneath it; the magnitude of the negative deflection subsequently decreases, returning to an isoelectric baseline at the end of depolarization.",
"     </li>",
"     <li>",
"      The third pair of electrodes, located at the end of the muscle strip, sees the electrical signal continuously moving towards it. Thus, it records a positive deflection that increases in magnitude as the dipole approaches it until the very end of depolarization when the potential returns to an isoelectric baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These depolarization waves, with associated positive and negative signal projections, are recorded on the surface ECG; P waves are generated within the atrial myocardium, while QRS complexes are generated within the ventricular myocardium. The dipole moves in the opposite direction during repolarization, and, therefore, the deflection generated on the surface ECG is in the opposite direction. This corresponds to the T wave, and when recorded directly from the muscle strip its direction is opposite to that of the QRS complex. On the surface ECG, however, the T wave is oriented in relatively the same direction (QRS-T concordance) as the QRS complex since depolarization in the intact heart begins at the endocardium and moves towards the epicardium, while repolarization begins at the epicardium and moves towards the endocardium.",
"   </p>",
"   <p>",
"    Thus, information about the direction of the moving dipole and its magnitude (dependent upon its proximity to the electrodes) are derived from the deflections recorded on the surface ECG. The theoretic basis of electrocardiography depends upon the assumptions that the heart is a single dipole generator, the body is a homogeneous conductor, and all electrodes are equidistant from the dipole generator. While none of the assumptions are entirely correct, they serve as the construct upon which the science of electrocardiography is based.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIAC DEPOLARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sinus node spontaneously depolarizes, thereby initiating the electrical cycle of the heart. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6614?source=see_link\">",
"     \"Anatomy and electrophysiology of the sinoatrial node\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9283?source=see_link\">",
"     \"ECG tutorial: Physiology of the conduction system\"",
"    </a>",
"    .) The impulse spreads through the atria via specialized conduction pathways and the interatrial bundle of Bachmann; this creates the P wave, which represents right and left atrial activation or depolarization, and results in contraction of the atria. As the electrical signal reaches the AV node, the impulse is delayed (the PR segment on the ECG), thereby allowing the ventricles to fill via atrial contraction. The wavefront of depolarization finally spreads via the His-Purkinje system to the ventricles, resulting in uniform ventricular activation and contraction. QRS deflections on the electrocardiogram correspond to depolarization of the ventricles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the beginning of ventricular activation, the septum is the first structure to depolarize, resulting in a negative deflection (q wave) in leads that look from a left to right direction on the ECG (ie, Leads I, aVL, and V5-V6). The mass of the ventricles subsequently depolarizes; a large positive deflection (R wave) results because of the larger mass of the left ventricle compared to that of the right ventricle. Repolarization occurs after a delay (the ST segment on the ECG), and results in the T wave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ECG LEADS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram records the electrical field over time as it is generated by all the cells of the heart. Instead of electrodes placed next to the muscle strip, there are standard lead systems that record the potential generated by the heart at the body surface. The most widely used system was developed by Willem Einthoven, the father of modern electrocardiography, although it was modified in subsequent years. Einthoven described a system of three bipolar leads located at the right arm, left arm and left leg (the right leg is a ground) to form a triangle (Einthoven's triangle). In addition to the original three bipolar leads, the standard 12-lead electrocardiogram now records three augmented limb leads and six precordial (chest) leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Limb leads",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limb lead electrodes are placed on the arms and legs distal to the shoulders and hips. In Einthoven's triangle, lead I records the difference between the right arm and the left arm (impulses directed toward the left generate a positive waveform), lead II between the right arm and left leg (impulses directed toward the leg or downward generate a positive waveform), and lead III between the left arm and left leg (impulses directed toward the leg or downward generate a positive waveform) (",
"    <a class=\"graphic graphic_figure graphicRef65289 \" href=\"mobipreview.htm?41/57/42896\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A \"reference electrode\", also called the Wilson&rsquo;s central terminal, is created for the augmented leads by connecting the three limb electrodes (right arm [R], the left arm [L] and the left leg [F]) which, when summated, give zero potential (",
"    <a class=\"graphic graphic_figure graphicRef69615 \" href=\"mobipreview.htm?28/25/29073\">",
"     figure 3",
"    </a>",
"    ). The electrical signals for the augmented leads are created by disconnecting the exploring electrode from the reference electrode. Put another way, the augmented leads use a limb electrode for one electrode and the average of the other two limb electrodes as the other electrode (ie, aVF is the difference between the left leg and the average of right arm and left arm electrodes). The three augmented leads are designated aVR, aVL and aVF. Impulses directed toward the augmented lead generate a positive waveform, while a negative waveform is generated if the impulse moves away from the lead.",
"   </p>",
"   <p>",
"    The three bipolar limb leads and the three augmented limb leads can be assembled into a hexaxial reference system:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lead I, directed horizontally right to left, is the 0&ordm; line.",
"     </li>",
"     <li>",
"      Lead II is 60&ordm;",
"     </li>",
"     <li>",
"      Lead III is 120&ordm;",
"     </li>",
"     <li>",
"      Lead aVF is 90&ordm;",
"     </li>",
"     <li>",
"      Lead aVL is -30&ordm;",
"     </li>",
"     <li>",
"      Lead aVR is -150&ordm;.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, these six leads divide the heart into 30 degree sectors and view the electrical field in a frontal plane (eg, right, left, superior, and inferior).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Precordial leads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precordial leads use the same reference electrode as the augmented limb leads (eg, the Wilson central terminal) (",
"    <a class=\"graphic graphic_figure graphicRef63119 \" href=\"mobipreview.htm?24/58/25505\">",
"     figure 4",
"    </a>",
"    ). The exploring electrodes are connected to the chest wall as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      V1 &mdash; fourth intercostal space to the right of the sternum",
"     </li>",
"     <li>",
"      V2 &mdash; fourth intercostal space to the left of the sternum",
"     </li>",
"     <li>",
"      V3 &mdash; midway between V2 and V4",
"     </li>",
"     <li>",
"      V4 &mdash; fifth intercostal space at the midclavicular line",
"     </li>",
"     <li>",
"      V5 &mdash; anterior axillary line at the level of V4, or halfway between V4 and V6 if the anterior axillary line is unclear.",
"     </li>",
"     <li>",
"      V6 &mdash; midaxillary line at the level of V4",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, these electrodes measure the electrical field in a horizontal plane (eg, right to left, anterior to posterior).",
"   </p>",
"   <p>",
"    Additional leads can be used in certain situations. As an example, right sided precordial leads (RV1-RV6) are helpful for establishing right ventricular infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .) Leads V7 (left posterior axillary line), V8 (tip of the left scapula), and V9 (to the left of the vertebra) are useful for diagnosing a true posterior wall infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37220/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8495765\">",
"    <span class=\"h1\">",
"     FILTERING",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ECG is obtained analog and, in current machines, is converted into a digital signal, where it is filtered to block out some of the &ldquo;noise&rdquo; while keeping relevant parts of the &ldquo;signal&rdquo;. Low frequency signals such as respiration are eliminated using a high pass filter. High frequency signals such as noncardiac muscle potentials are attenuated using a low pass filter. Specific &ldquo;notch&rdquo; filters that eliminate electromagnetic interference at 50 to 60 Hz may also be used.",
"   </p>",
"   <p>",
"    Digital ECG data may also be compressed when sent to a database to be retrieved for later use. Therefore, there may be a small difference in appearance of an ECG printed at the bedside versus one downloaded from an electronic medical record [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37220/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345668062\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The electrocardiogram (ECG) provides a graphic record of the electrical activity of the heart. Each cardiac cell generates an action potential as it becomes depolarized and then repolarized during a normal cycle. Depolarization of cardiac cells proceeds in an orderly fashion in the normal situation beginning in the sinus node, and then spreading sequentially through the atria, AV node, and ventricles. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sequential movement of electrical current with each depolarization, from the sinus node to the entire ventricular myocardium, creates specific phases of the ECG: P wave, PR segment, QRS complex, ST segment, and T wave. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiac depolarization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The electrical activity of the heart is captured by recording electrodes or &ldquo;leads&rdquo; placed on both arms and legs (called the limb leads), and six on the chest (called the precordial leads). The twelve lead electrocardiogram is created by simultaneously comparing electrical activity from two of these in the following manner:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lead I&mdash;left arm compared to right arm (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Limb leads'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Lead II&mdash;left leg compared to right arm",
"     </li>",
"     <li>",
"      Lead III&mdash;left leg compared to left arm",
"     </li>",
"     <li>",
"      Lead aVR&mdash;right arm to the average of left arm and left leg electrodes",
"     </li>",
"     <li>",
"      Lead aVL&mdash;left arm to the average of the right arm and left leg electrodes.",
"     </li>",
"     <li>",
"      Lead aVF&mdash;left leg to the average of the right arm and left arm electrodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The precordial leads, V1-V6, compare electrical activity with one place on the chest to the reference electrode (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Precordial leads'",
"    </a>",
"    above)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8495656\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37220/abstract/1\">",
"      Casas RE, Marriott HJ, Glancy DL. Value of leads V7-V9 in diagnosing posterior wall acute myocardial infarction and other causes of tall R waves in V1-V2. Am J Cardiol 1997; 80:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37220/abstract/2\">",
"      Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2007; 49:1109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2117 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37220=[""].join("\n");
var outline_f36_22_37220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H345668062\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELECTRICAL FIELDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIAC DEPOLARIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ECG LEADS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Limb leads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Precordial leads",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8495765\">",
"      FILTERING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H345668062\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8495656\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2117|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/1/19486\" title=\"figure 1\">",
"      Electrical fields",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/57/42896\" title=\"figure 2\">",
"      Bipolar limb leads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/25/29073\" title=\"figure 3\">",
"      Augmented limb leads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/58/25505\" title=\"figure 4\">",
"      Precordial chest leads",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2117|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?31/46/32481\" title=\"movie 1\">",
"      Generation of the myocardial action potential",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6614?source=related_link\">",
"      Anatomy and electrophysiology of the sinoatrial node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/262?source=related_link\">",
"      Basic principles of electrocardiographic interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22038?source=related_link\">",
"      ECG tutorial: Intraventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9283?source=related_link\">",
"      ECG tutorial: Physiology of the conduction system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10344?source=related_link\">",
"      Right bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_22_37221="Mucosal leishmaniasis";
var content_f36_22_37221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucosal leishmaniasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37221=[""].join("\n");
var outline_f36_22_37221=null;
var title_f36_22_37222="Glyburide: Pediatric drug information";
var content_f36_22_37222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glyburide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"    see \"Glyburide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/38/15973?source=see_link\">",
"    see \"Glyburide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DiaBeta&reg;;",
"     </li>",
"     <li>",
"      Glynase&reg; PresTab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Glyburide&reg;;",
"     </li>",
"     <li>",
"      DiaBeta&reg;;",
"     </li>",
"     <li>",
"      Dom-Glyburide;",
"     </li>",
"     <li>",
"      Euglucon&reg;;",
"     </li>",
"     <li>",
"      Med-Glybe;",
"     </li>",
"     <li>",
"      Mylan-Glybe;",
"     </li>",
"     <li>",
"      Novo-Glyburide;",
"     </li>",
"     <li>",
"      Nu-Glyburide;",
"     </li>",
"     <li>",
"      PMS-Glyburide;",
"     </li>",
"     <li>",
"      PRO-Glyburide;",
"     </li>",
"     <li>",
"      ratio-Glyburide;",
"     </li>",
"     <li>",
"      Riva-Glyburide;",
"     </li>",
"     <li>",
"      Sandoz-Glyburide;",
"     </li>",
"     <li>",
"      Teva-Glyburide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Sulfonylurea",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypoglycemic Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"      see \"Glyburide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Formulations of micronized glyburide (Glynase&reg; Prestab&reg;) are",
"     <b>",
"      not",
"     </b>",
"     bioequivalent with conventional formulations (eg, Dia&beta;eta&reg;) and dosage should be retitrated when transferring patients from one formulation to the other",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Management of noninsulin-dependent diabetes mellitus in patients",
"     <b>",
"      previously untreated",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet (Dia&beta;eta&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 2.5-5 mg/day; in patients who are more sensitive to hypoglycemic drugs, start at 1.25 mg/day; increase in increments of no more than 2.5 mg/day at weekly intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: 1.25-20 mg/day given as single or divided doses; maximum: 20 mg/day; doses &gt;10 mg should be divided into twice daily doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micronized tablets (Glynase&reg; Prestab&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 1.5-3 mg/day; in patients who are more sensitive to hypoglycemic drugs, start at 0.75 mg/day; increase in increments of no more than 1.5 mg/day at weekly intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: 0.75-12 mg/day given as a single dose or in divided doses; maximum: 12 mg/day; doses &gt;6 mg/day should be divided into twice daily doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Management of noninsulin-dependent diabetes mellitus in patients",
"     <b>",
"      previously maintained on insulin:",
"     </b>",
"     Initial dosage dependent upon previous insulin dosage, see table",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Previous Daily Insulin Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (units)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Initial Glyburide Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg conventional formulation)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Initial Glyburide Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg micronized formulation)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Insulin Dosage Change",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (after glyburide started)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.5-3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (increase in increments of 1.25-2.5 mg every 2-10 days)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (increase in increments of 0.75-1.5 mg every 2-10 days)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Reduce insulin dosage by 50% (gradually taper off insulin as glyburide dosage increased)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use conservative initial and maintenance doses and avoid use in severe disease",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1.25 mg, 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DiaBeta&reg;: 1.25 mg, 2.5 mg, 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [micronized]: 1.5 mg, 3 mg, 5 mg, 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glynase&reg; PresTab&reg;: 1.5 mg, 3 mg, 6 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food every morning 30 minutes before breakfast or the first main meal",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to diet and exercise for the management of type II diabetes mellitus (noninsulin-dependent, NIDDM); may be used concomitantly with metformin or insulin to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F176756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GlyBURIDE may be confused with glipiZIDE, Glucotrol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dia&beta;eta&reg; may be confused with Zebeta&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Micronase may be confused with microK&reg;, miconazole, Micronor&reg;, Microzide&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F176754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, erythema, maculopapular eruptions, morbilliform eruptions, photosensitivity reaction, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Disulfiram-like reaction, hypoglycemia, hyponatremia (SIADH reported with other sulfonylureas)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, epigastric fullness, heartburn, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Nocturia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, pancytopenia, porphyria cutanea tarda, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatitis, liver failure, transaminase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuretic effect (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glyburide, any component, or other sulfonamides; type 1 diabetes mellitus (insulin-dependent, IDDM), diabetic ketoacidosis with or without coma; concomitant use with bosentan",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with adrenal or pituitary insufficiency; hypoglycemic reactions are more prevalent in debilitated, malnourished patients, patients with mild disease or impaired hepatic or renal function; hypoglycemia may also occur with inadequate caloric intake, strenuous exercise, or concurrent use with other hypoglycemic drugs; patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling; however, there is a risk of cross-reaction in patients with allergies to any of these compounds; avoid use when the previous reaction has been severe; product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin; data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association. Formulations of micronized glyburide (Glynase&reg; Prestab&reg;) are not bioequivalent with conventional formulations (eg, Dia&beta;eta&reg;) and dosage should be retitrated when transferring patients from one formulation to the other.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F176743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: GlyBURIDE may enhance the hepatotoxic effect of Bosentan. Bosentan may increase the metabolism of GlyBURIDE. GlyBURIDE may increase the metabolism of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of GlyBURIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of GlyBURIDE. Management: Administer glyburide at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer dependent) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies differ by manufacturer labeling. Because adverse events were not observed in animal reproduction studies, one manufacturer classifies glyburide as pregnancy category B. Because adverse events were noted in animal studies during the period of lactation, another manufacturer classifies glyburide as pregnancy category C.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Glyburide was not found to significantly cross the placenta",
"     <i>",
"      in vitro",
"     </i>",
"     and was not found in the cord serum infants of mothers taking glyburide for gestational diabetes mellitus (GDM). Nonteratogenic effects such as hypoglycemia in the neonate have been associated with maternal glyburide use. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. The manufacturer recommends that if glyburide is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date. Although studies have shown positive outcomes using glyburide for the treatment of GDM, use may not be appropriate for all women. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of type 2 diabetes mellitus during pregnancy. Insulin is considered the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypoglycemia, fasting blood glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1058980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Target range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Blood glucose: Fasting and preprandial: 80-120 mg/dL; bedtime: 100-140 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glycosylated hemoglobin (hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ): &lt;7%",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells, reduces glucose output from the liver, and increases insulin sensitivity at peripheral target sites",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 45-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 1.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Conventional formulations: 16-24 hours; micronized formulations: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Average decrease in fasting blood glucose (when used as monotherapy): 60-70 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Reliably and almost completely absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.125 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Completely metabolized to one moderately active and several inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: High (&gt;99%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Biphasic: Terminal elimination half-life: Average: 1.4-1.8 hours (range: 0.7-3 hours); may be prolonged with renal or hepatic insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Conventional formulation: 4 hours; micronized formulation: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 30% to 50% of dose excreted in the urine as metabolites in first 24 hours; the remainder of the metabolite via biliary excretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/38/15973?source=see_link\">",
"      see \"Glyburide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not change dose or discontinue without consulting prescriber; avoid alcohol while taking this medication, may cause severe reaction; maintain regular dietary intake and exercise routine; always carry quick source of sugar; if experiencing a hypoglycemic reaction, contact prescriber immediately; report severe or persistent side effects, extended vomiting or flu-like symptoms, skin rash, easy bruising or bleeding, or change in color of urine or stool. May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When transferring from other sulfonylurea antidiabetic agents to glyburide, with the exception of chlorpropamide, the administration of the other agent may be abruptly discontinued; due to the prolonged elimination half-life of chlorpropamide, a 2- to 3-day drug-free interval may be advisable before glyburide therapy is begun",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1999, 131(4):281-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/22/37222/abstract-text/10454950/pubmed\" id=\"10454950\" target=\"_blank\">",
"        10454950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/22/37222/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13336 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37222=[""].join("\n");
var outline_f36_22_37222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176698\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176699\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058978\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058972\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176673\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176659\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058982\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058981\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176756\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176754\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058986\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058971\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058970\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176743\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176668\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058989\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176669\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176684\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058977\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058980\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058969\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058984\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058985\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058976\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058987\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13336|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=related_link\">",
"      Glyburide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/38/15973?source=related_link\">",
"      Glyburide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_22_37223="Antiviral medications for the treatment of hepatitis B in the HIV-infected patient";
var content_f36_22_37223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiviral medications for the treatment of hepatitis B in the HIV-infected patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37223/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37223/contributors\">",
"     Barbara H McGovern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37223/contributors\">",
"     Kenneth E Sherman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37223/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37223/contributors\">",
"     David Thomas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37223/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/22/37223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H33400409\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The era of highly active antiretroviral therapy (ART) has led to declining rates of opportunistic infections and a new focus on other leading causes of morbidity, such as end-stage liver disease (ESLD) secondary to hepatitis B virus (HBV) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/1\">",
"     1",
"    </a>",
"    ]. The treatment and prevention of hepatitis B has taken on great significance in light of the negative impact HIV has on the natural history of chronic hepatitis B infection.",
"   </p>",
"   <p>",
"    However, the use of antiviral medications for hepatitis B is complicated by the fact that some of these agents have dual activity against HIV infection. Also the available agents vary widely in efficacy and safety.",
"   </p>",
"   <p>",
"    This topic will address the clinical data available on the various antiviral agents. Information on the evaluation of the treatment candidate, treatment approach, and patient monitoring, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44020?source=see_link\">",
"     \"Evaluation of chronic hepatitis B virus infection in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6119?source=see_link\">",
"     \"Monitoring the HIV-infected patient with chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunizations in HIV-infected patients\", section on 'Hepatitis B vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16836793\">",
"    <span class=\"h1\">",
"     TENOFOVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    has activity against both HIV and HBV. Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , tenofovir is a nucleotide reverse transcriptase inhibitor with activity against",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The efficacy and safety of tenofovir has been evaluated in small substudies within two phase III clinical trials of tenofovir for the treatment of HIV in antiretroviral-naive and experienced patients.",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients treated with tenofovir experienced significant HBV viral load declines compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/2\">",
"     2",
"    </a>",
"    ]. Tenofovir was also effective against lamivudine resistant virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Development of resistance to tenofovir has not been demonstrated in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfection, but the duration of treatment in these small trials was only 24 weeks.",
"   </p>",
"   <p>",
"    These data prompted a randomized, double-blind placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in 52",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    co-infected patients on stable HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/7\">",
"     7",
"    </a>",
"    ]. At baseline, median serum HBV DNA levels were 8.7 log(10)",
"    <span class=\"nowrap\">",
"     copies/microL",
"    </span>",
"    and 9.3 log(10)",
"    <span class=\"nowrap\">",
"     copies/microL",
"    </span>",
"    in the adefovir and tenofovir arms, respectively. After a median duration of follow-up of 75 weeks, mean log HBV DNA declines were -4.4 logs and -3.2 logs on tenofovir and adefovir, respectively.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    has been associated with modest changes in renal function, although these have rarely been treatment limiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    should only be used in the context of a multidrug ART regimen due to its ability to select for HIV resistance mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33400432\">",
"    <span class=\"h1\">",
"     LAMIVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    (3TC, Epivir) has demonstrated efficacy against HBV infection in both HBeAg-positive and HBeAg-negative patients and is well tolerated. The major issue related to lamivudine is the rapid emergence of drug resistance when used within ART as the only HBV-active agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    has dual efficacy against hepatitis B and HIV infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The activity of lamivudine was illustrated in the CAESAR trial, which examined the efficacy of adding lamivudine 150 mg twice daily to background",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    therapy for the treatment of HIV in 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/9\">",
"     9",
"    </a>",
"    ]. Of 1790 study subjects, 122 (seven percent) were HBsAg-positive. Retrospective analysis of frozen samples demonstrated that at 12 weeks of treatment, the median log 10 HBV DNA decline was 2.0 in the lamivudine group compared to no reduction in the placebo group.",
"   </p>",
"   <p>",
"    Histologic responses and seroconversion rates from HBeAg-positive to negative are difficult to estimate since this has not been studied rigorously in HIV-infected patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ; however, HBeAg seroconversion rates appear low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The greatest problem with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    for either HIV or HBV is its low genetic barrier to resistance. In a retrospective analysis of 81 chronically infected",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients on lamivudine, 53 (65 percent) had detectable HBV DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/14\">",
"     14",
"    </a>",
"    ]. Higher levels of viremia were associated with lower nadir CD4 counts, but not with duration of lamivudine treatment. Mutations in the HBV polymerase gene known to confer resistance to lamivudine were detected in 39 of 53 (74 percent) of HBV viremic patients and the incidence of mutations progressively increased with longer duration of treatment (50 percent for &lt;2 years; 73 percent for two to four years; and 94 percent for &gt;4 years). In addition, increasing numbers of mutations were associated with a greater increase in CD4 cell count from baseline. This association may reflect increased selective pressure for viral mutants secondary to HAART-associated immune reconstitution.",
"   </p>",
"   <p>",
"    The emergence of HIV resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    occurs with a single mutation, M184V in the YMDD motif near the catalytic site of the reverse transcriptase enzyme. Unfortunately, the use of lamivudine-containing HAART in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients is also associated with the rapid emergence of HBV-related drug resistance due to one mutation within the YMDD motif of reverse transcriptase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The primary lamivudine resistance mutations are located at M204, with the methionine replaced by either an isoleucine or a valine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/15\">",
"     15",
"    </a>",
"    ]. Secondary compensatory mutations include L180M,",
"    <span class=\"nowrap\">",
"     L80V/L,",
"    </span>",
"    I169T, V173L, S202I and",
"    <span class=\"nowrap\">",
"     T184S/G;",
"    </span>",
"    all are found in association with",
"    <span class=\"nowrap\">",
"     M204V/I.",
"    </span>",
"    The I169T, S202I and",
"    <span class=\"nowrap\">",
"     T184S/G",
"    </span>",
"    mutations also contribute to entecavir resistance. The A181T mutation can occur in the absence of",
"    <span class=\"nowrap\">",
"     M204V/I",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/16\">",
"     16",
"    </a>",
"    ] and can confer resistance to adefovir as well.",
"   </p>",
"   <p>",
"    The emergence of resistance is more common in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients than in HBV monoinfected patients. In one study that prospectively evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    for HBV infection in patients initiating lamivudine-containing HAART for HIV disease, HBV DNA was suppressed in 57 of 66 patients after two months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/12\">",
"     12",
"    </a>",
"    ]. However, 22 of 24 patients developed lamivudine resistance with evidence of mutations in the YMDD motif of HBV after five years of treatment, mean rate of 20 percent per year. The development of lamivudine resistance in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients has been associated with duration of treatment; no relationship between baseline HBV DNA level, aminotransferases, or CD4 cell count has been seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance or the withdrawal of lamivudine therapy has been associated with exacerbations of hepatitis and hepatic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In patients who are treated with lamivudine for HIV infection, drug holidays can have devastating effects if the patient and the clinician are unaware of the patient's underlying chronic HBV status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is generally dosed at 300 mg daily for patient convenience, although 150 mg twice daily was the original dose when the medication was first approved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33400898\">",
"    <span class=\"h1\">",
"     EMTRICITABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     Emtricitabine",
"    </a>",
"    (FTC) is closely related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , but has a longer serum half-life. It is also active against HBV and is well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/20\">",
"     20",
"    </a>",
"    ]. However, due to its structural similarity to lamivudine, any patient who is lamivudine-resistant should",
"    <strong>",
"     not",
"    </strong>",
"    be considered for FTC therapy due to cross-resistance.",
"   </p>",
"   <p>",
"    In three 48-week studies evaluating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    as part of triple drug therapy for HIV, 39 HBsAg-positive patients were identified out of more than 1000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/21\">",
"     21",
"    </a>",
"    ]. Seventeen patients were available for evaluation at week 48, 14 of whom (82 percent) had a greater than 5 log(10) decline in HBV DNA, or had HBV DNA below the level of detection (less than 4700",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    Genotypic analysis of seven patients who had detectable viremia at 48 weeks demonstrated a mutation in the",
"    <span class=\"nowrap\">",
"     M204V/I",
"    </span>",
"    while none developed dual mutations",
"    <span class=\"nowrap\">",
"     (M204V/I",
"    </span>",
"    with L180M).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33400926\">",
"    <span class=\"h1\">",
"     ADEFOVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    is less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in both HBeAg-positive and HBeAg-negative patients with chronic hepatitis B but is associated with lower rates of resistance mutations than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . Signature mutations for adefovir are N236T and A181V. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety and efficacy of a 10 mg daily dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    for the treatment of HIV-infected patients with chronic hepatitis B was assessed in an open label trial of 35 subjects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients continued to receive lamivudine as part of their HAART regimen while they initiated adefovir. Four patients withdrew from the study, two due to side effects. A four-log decline in hepatitis B viremia was seen in the remaining 31 patients who were treated for 48 weeks. HBeAg-seroconversion occurred in two patients. Further follow-up of 29 patients who continued adefovir for 144 weeks demonstrated ongoing HBV suppression without evidence of adefovir-associated resistance mutations in HBV DNA polymerase or HIV-1 reverse transcriptase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    (60 to 120 mg) used in patients with HIV infection alone have had only modest efficacy and significant renal toxicity; thus, the development of adefovir for treatment of HIV was halted. In contrast, the 10 mg dose used in the study above of patients with HBV and HIV was well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/22\">",
"     22",
"    </a>",
"    ]. Two patients experienced mild reversible changes in creatinine that may have been related to other concomitant medications.",
"   </p>",
"   <p>",
"    One concern regarding the use of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    has been the potential introduction of HIV resistance mutations to the closely related antiretroviral drug,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . A substudy was performed of 13 patients in the adefovir treatment trial who had detectable HIV viremia despite the administration of HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/24\">",
"     24",
"    </a>",
"    ]. No evidence of adefovir-associated resistance mutations at reverse transcriptase codons K65R or K70E were observed in these isolates.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    (10 mg daily) is one of the drugs of choice in",
"    <span class=\"nowrap\">",
"     HBV/HIV",
"    </span>",
"    coinfected patients who do NOT require ART at the time of evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33400954\">",
"    <span class=\"h1\">",
"     ENTECAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    is a potent and selective inhibitor of hepatitis B polymerase. Entecavir has demonstrated efficacy against HBeAg-positive and HBeAg-negative patients. Viral load suppression is of a higher magnitude than that seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the original package insert for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    indicated no anti-HIV activity by in vitro testing at clinically relevant concentrations, a one-log drop in HIV RNA was reported in three separate patients who were taking entecavir monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/25\">",
"     25",
"    </a>",
"    ]. This clinical observation led to extensive in vitro testing by one research group, which demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"       Entecavir",
"      </a>",
"      inhibited HIV replication with an inhibitory concentration (IC50) between 0.1 and 1 nM, which is 100- to 1000-fold lower than the IC50 for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Clonal sequence analysis of the clinical isolates from one patient demonstrated emergence of the M184V mutation while on therapy. Since this individual had received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      in the distant past, it is unclear if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      selected a new mutation or one that had been already archived.",
"     </li>",
"     <li>",
"      Both laboratory and a patient-derived strain with the M184V mutation were resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      . In vitro testing suggests that entecavir acts at or before the reverse transcription step.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent study was performed of 10 ART-naive and seven ART-experienced",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients in the United States and Australia who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/26\">",
"     26",
"    </a>",
"    ]. Median viral load reductions in HIV RNA of approximately one log were seen in both groups of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/26\">",
"     26",
"    </a>",
"    ]. Polymerase sequencing showed selection of the M184V mutation in three treatment-naive and three treatment-experienced patients. Until further laboratory confirmation is available, these preliminary data have immediate implications for the use of entecavir in HIV-infected patients who have detectable HIV RNA on antiretroviral therapy or who are not on HIV treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an ongoing trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    for the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV, 68",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients received either 1 mg of entecavir or placebo once daily for 24 weeks, followed by open-label entecavir for 24 additional weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients in the entecavir arm achieved significant reductions in HBV DNA at week 24 compared with placebo (-3.6 versus +0.11 log",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    The proportion of patients with less than 400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or a greater than two-log drop in HBV viremia was also higher in the entecavir group (84 versus zero percent). No significant changes in HIV RNA were noted in either group.",
"   </p>",
"   <p>",
"    No resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    was observed after one year in treatment-na&iuml;ve patients. In comparison, resistance was observed in seven percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -refractory patients after one year. Thus, the risk of entecavir resistance is higher in patients with prior lamivudine drug resistance.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    is not associated with renal toxicity; however, dose reduction is required for patients with a creatinine clearance less than 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33400968\">",
"    <span class=\"h1\">",
"     TELBIVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the GLOBE trial, 1370 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    (600 mg once daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (100 mg once daily) for up to 104 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/28\">",
"     28",
"    </a>",
"    ]. Approximately one-third of these patients were HBeAg-negative.",
"   </p>",
"   <p>",
"    The mean reduction in HBV DNA from baseline was greater than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (-6.45 versus -5.54 log10",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    This was also correlated with a lower risk of drug resistance, which may have been related to more rapid viral suppression. This concept, of decreasing risk of drug resistance with potent viral suppression, has been illustrated repeatedly in clinical trials of HIV therapy over the past two decades. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proportion of patients with ALT normalization, HBeAg seroconversion, HBeAg loss, and histologic improvement was similar in both groups.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/15/3317?source=see_link\">",
"     Telbivudine",
"    </a>",
"    selects for the M204I mutation, as seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . The role of telbivudine monotherapy is limited due to its high resistance rate (compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ), cross-resistance with lamivudine, and higher price (compared with lamivudine).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/15/3317?source=see_link\">",
"     Telbivudine",
"    </a>",
"    does not have intrinsic activity against HIV in vitro. However, no clinical trials of telbivudine therapy in HIV-infected patients with detectable HIV RNA have been performed. Furthermore, in one case report, the administration of",
"    <span class=\"nowrap\">",
"     telbivudine/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"      adefovir",
"     </a>",
"    </span>",
"    combination therapy was temporally associated with declines in HIV RNA in a patient with untreated",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/29\">",
"     29",
"    </a>",
"    ]. Since telbivudine can select for mutations in the YMDD motif, it is not a recommended treatment for the coinfected patient at present pending further study. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11389507\">",
"    <span class=\"h1\">",
"     INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard interferon and peginterferon have demonstrated efficacy in the treatment of HBeAg-positive and HBeAg-negative patients, however the use of interferon therapy is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients with decompensated cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are little published data on the efficacy of interferon-based therapies for the treatment of HBV in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/30\">",
"     30",
"    </a>",
"    ]. In the few studies that have included HIV-infected patients, low numbers of subjects were enrolled, different dosing regimens and treatment durations were used, CD4 counts were often not recorded, and most were published in the era prior to potent ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. Therefore, it is difficult to identify predictors of response or appropriate candidates based on this information.",
"   </p>",
"   <p>",
"    One retrospective cohort study examined the effect of HIV status on outcome after six months of standard interferon for the treatment of HBV infection in 26 HIV-seropositive patients compared with 50 HIV-negative subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/36\">",
"     36",
"    </a>",
"    ]. Response rates in terms of viral load suppression were not significantly different according to HIV status, although there was a trend toward improved response in HIV-negative patients that may have become significant in a larger study. Even with this small cohort, sustained HBeAg seroconversion only occurred in HIV-negative patients.",
"   </p>",
"   <p>",
"    The only characteristics that differentiated the HIV-infected patients who responded to interferon from those who did not respond were higher pretreatment CD4 cell counts and higher necroinflammatory scores on baseline liver biopsy. Age, duration of HBV infection, HBV DNA level, alcohol use, and degree of histologic fibrosis did not differentiate responders from nonresponders.",
"   </p>",
"   <p>",
"    Peginterferon alfa 2a at 180 ugm SQ weekly for 48 weeks is effective in the treatment of HBeAg-positive and HBeAg-negative patients who are HIV-seronegative and is the only peginterferon that has been approved for this treatment indication. There are no data on the use of peginterferon in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients, although they have been used for the treatment of hepatitis C in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37223/abstract/37\">",
"     37",
"    </a>",
"    ]. Peginterferons should be given with caution in patients with active depression, uncontrolled diabetes, cardiac, or pulmonary disease. The relative and absolute contraindications for the use of interferon therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/1\">",
"      Weber R, Sabin CA, Friis-M&oslash;ller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/2\">",
"      Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/3\">",
"      N&uacute;&ntilde;ez M, P&eacute;rez-Olmeda M, D&iacute;az B, et al. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/4\">",
"      Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/5\">",
"      Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003; 17:F7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/6\">",
"      Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186:1844.",
"     </a>",
"    </li>",
"    <li>",
"     Peters, M, Anderson, J, Lynch, P, et al. Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are coinfected with HIV: Results of ACTG A5127. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2005; abstract #124.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/8\">",
"      Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/9\">",
"      Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/10\">",
"      Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/11\">",
"      Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001; 32:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/12\">",
"      Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/13\">",
"      Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/14\">",
"      Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/15\">",
"      Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12 Suppl 3:H15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/16\">",
"      Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/17\">",
"      Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/18\">",
"      Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/19\">",
"      McGovern B. What drives hepatitis B virus-related hepatic flares? Virus, T cells--or a bit of both? Clin Infect Dis 2004; 39:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/20\">",
"      Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 2006; 42:126.",
"     </a>",
"    </li>",
"    <li>",
"     Snow, A, Harris, J, Borroto-Esoda, K, et al. Emtricitabine therapy for hepatitis infection in HIV+ patients co-infected with hepatitis B virus: efficacy and genotypic findings in antiretroviral treatment-naive patients. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA Abstract #836.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/22\">",
"      Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/23\">",
"      Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/24\">",
"      Delaugerre C, Marcelin AG, Thibault V, et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002; 46:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/25\">",
"      McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356:2614.",
"     </a>",
"    </li>",
"    <li>",
"     Audsley, J, Sasadeusa, J, Mijch, A, et al. The anti-HIV activity of entecavir: serum HIV RNA decreases and selection of the M184V mutation occurs in both ART-naive and experienced HIV/HBV coinfected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 3-6, 2008; abstract #63.",
"    </li>",
"    <li>",
"     Pessoa, W, Gazzard, B, Huang, A, et al. Entecavir in HIV/HBV co-infected patients: safety and efficacy in a phase II study (ETV-038). Presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2005; abstract #123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/28\">",
"      Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576.",
"     </a>",
"    </li>",
"    <li>",
"     Low, E. Telbivudine has activity against HIV. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 8-11th, 2009; abstract # 813a.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/30\">",
"      Piroth L, S&egrave;ne D, Pol S, et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007; 21:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/31\">",
"      Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/32\">",
"      Brook MG, McDonald JA, Karayiannis P, et al. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/33\">",
"      Brook MG, Chan G, Yap I, et al. Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ 1989; 299:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/34\">",
"      Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/35\">",
"      Porchon C, Kremsdorf D, Pol S, et al. Serum hepatitis C virus RNA and hepatitis B virus DNA in non-A, non-B post-transfusional and sporadic chronic hepatitis. J Hepatol 1992; 16:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/36\">",
"      Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37223/abstract/37\">",
"      Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16128 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37223=[""].join("\n");
var outline_f36_22_37223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33400409\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16836793\">",
"      TENOFOVIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33400432\">",
"      LAMIVUDINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33400898\">",
"      EMTRICITABINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33400926\">",
"      ADEFOVIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33400954\">",
"      ENTECAVIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33400968\">",
"      TELBIVUDINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11389507\">",
"      INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44020?source=related_link\">",
"      Evaluation of chronic hepatitis B virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6119?source=related_link\">",
"      Monitoring the HIV-infected patient with chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25750?source=related_link\">",
"      Telbivudine in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_22_37224="Control of red blood cell hydration";
var content_f36_22_37224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Control of red blood cell hydration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37224/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37224/contributors\">",
"     Carlo Brugnara, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37224/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37224/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/22/37224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume and hemoglobin concentration of human red blood cells are determined by the red cell content of hemoglobin, ions, and water. The water, cation, and anion contents are continuously regulated by the activity and interactions of several ion transport systems, as summarized in the figure (",
"    <a class=\"graphic graphic_figure graphicRef62852 \" href=\"mobipreview.htm?3/39/3711\">",
"     figure 1",
"    </a>",
"    ). The importance of these systems is indicated by the various diseases occurring when red cell ion transport is impaired (",
"    <a class=\"graphic graphic_table graphicRef80358 \" href=\"mobipreview.htm?12/39/12923\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The transport systems involved in regulating the volume and composition of red cells, and which affect the cation, anion, and water content of the red cell will be discussed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/1\">",
"     1",
"    </a>",
"    ]. A brief discussion of the role of ion transport in the pathogenesis of sickle cell disease will also be presented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Cation content",
"    </span>",
"    &nbsp;&mdash;&nbsp;In human red cells (and other cells), the activity of the sodium-K-ATPase pump maintains a low sodium, high potassium milieu. The outward potassium gradient and the inward sodium gradient can be used by several passive (gradient-driven) transport systems, which are sensitive to changes in pH, volume, or membrane integrity.",
"   </p>",
"   <p>",
"    Human red cells have a high content of total magnesium, but a lower content of free magnesium. Magnesium is an important regulator of several cellular functions, but little is known about the mechanisms involved in controlling the magnesium content of the human erythrocyte.",
"   </p>",
"   <p>",
"    A powerful membrane Ca-ATPase is responsible for the extremely low Ca content of human erythrocytes",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anion content",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chloride content of the human red cell varies according to the cation content (permeant cations), the net charge of the non-permeant ions (eg, hemoglobin and 2,3-bisphosphoglycerate (2,3-BPG)), and intracellular pH. The chloride-bicarbonate anion exchanger (AE1 or band 3 protein) is the major pathway for the movement of these anions in human red cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Water content",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water can move across the red cell membrane by passive diffusion and also via a specific water channel aquaporin-1 (AQP-1), which is the prototype of the aquaporin family of transporters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/2\">",
"     2",
"    </a>",
"    ]. Passive diffusion and water channels allow the red cell to be in osmotic equilibrium with the plasma. As a result, the water content of the human red cell is determined by the intracellular sodium, potassium, and Cl content and the osmolality of the plasma. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Water channels'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ENERGY-DRIVEN SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two active transport systems in the red cell: the Na-K-ATPase pump and the calcium-ATPase pump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     N-K-ATPase pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium-potassium ATPase is an enzyme formed by three subunits: the alpha-1 catalytic subunit (1020 amino acids) involved in ion transport, the beta-1 subunit (302 amino acids), involved in the interaction with membrane and cytoskeletal components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and the gamma-1 proteolipid subunit. Each red cell contains a mean of 228 to 470 Na-K-ATPase units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Na-K-ATPase pump extrudes sodium in exchange for potassium with a 3:2 stoichiometry. Tosteson and Hoffman provided theoretical and experimental evidence for the pump-leak model, which explains how active transport works in parallel with passive transport to determine the sodium and potassium content of cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/6\">",
"     6",
"    </a>",
"    ]. The cell sodium content is determined by the balance between the entry of sodium and its active extrusion by the Na-K pump.",
"   </p>",
"   <p>",
"    A demonstration of this model was provided by studies of the red cells of a patient with a 10 to 20-fold increase in the number of pump sites per cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/7\">",
"     7",
"    </a>",
"    ]. The red cell membranes had normal passive permeability to sodium and, due to increased Na-K-ATPase activity, a reduction in the cell sodium concentration and an elevation in the cell potassium concentration were present.",
"   </p>",
"   <p>",
"    Loss-of-function mutations in the nonerythroid alpha-2 subunit gene of the Na-K pump have been associated with familial hemiplegic migraine type 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], while missense mutations in the nonerythroid alpha-3 subunit gene have been associated with rapid-onset dystonia parkinsonism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ca-ATPase pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red cell membrane also contains a Ca-ATPase pump that maintains free cytosolic levels of calcium below 0.1",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/12\">",
"     12",
"    </a>",
"    ]. Calcium efflux via the Ca-ATPase pump takes place in conjunction with hydrogen influx, with a 1:1 stoichiometry between ATP consumption and calcium extrusion.",
"   </p>",
"   <p>",
"    The intracellular calcium concentration is increased two to threefold during deoxygenation in sickle cell anemia red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/13\">",
"     13",
"    </a>",
"    ]. This change is associated with an increase in passive calcium influx and a reduction in Ca-ATPase pump activity. It may contribute to the sickling process by activating a major dehydration pathway via the calcium-sensitive potassium channel (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Calcium-activated potassium channel'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There is great variability in the transport capacity of the Ca-ATPase pump within the same subject, with the presence of sub-populations of red cells in which the activity can vary six to ninefold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/14\">",
"     14",
"    </a>",
"    ]. It has been shown that aging of normal human red cells is associated with a monotonic decrease in Ca-ATPase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PASSIVE GRADIENT-DRIVEN SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several passive, gradient-driven systems, including electroneutral cotransporters and ion- or water-specific channels, utilize the inward sodium and outward potassium gradients generated by the Na-K pump to transport ions across the red cell membrane. Because of the dependence upon the Na-K pump, this process is also called secondary active transport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Na-K-Cl cotransport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Na-K-Cl cotransport was first described in human red cells in 1974 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/16\">",
"     16",
"    </a>",
"    ] and is widely distributed in other cell types, including the apical and basolateral membranes of the thick ascending limb of the loop of Henle. The major erythroid form of this electroneutral transporter, called NKCC, has a 1Na:1K:2Cl stoichiometry. As with its counterpart in the basolateral membrane of the thick ascending limb, it is inhibited with high affinity by loop diuretics, which bind to the Cl site, and belongs to the family of cation-chloride cotransporters (CCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]; other members of this family are the thiazide-sensitive Na-Cl cotransporter (NCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/19\">",
"     19",
"    </a>",
"    ], the volume-sensitive K-Cl cotransporter (KCC, see below), and the apical Na-K-Cl cotransporter of the renal thick limb NKCC2, which typically has a lower affinity for loop diuretics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In human red cells, Na-K-Cl cotransport results in a small net extrusion of sodium, potassium, and chloride under physiologic conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/21\">",
"     21",
"    </a>",
"    ]. It plays only a minor role in the regulation of human red cell volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     K-Cl cotransport",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electroneutral K-Cl cotransporter belongs to the family of chloride-cation transporters (CCC). At least four major isoforms of this transporter have been identified: KCC1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/22\">",
"     22",
"    </a>",
"    ], KCC2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/23\">",
"     23",
"    </a>",
"    ], KCC3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/24\">",
"     24",
"    </a>",
"    ], and KCC4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/25\">",
"     25",
"    </a>",
"    ]. The importance of these transporters has been shown in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The KCC2",
"      <span class=\"nowrap\">",
"       (-/-)",
"      </span>",
"      mouse dies perinatally due to respiratory failure induced by the loss of synaptic inhibitory input [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The KCC3",
"      <span class=\"nowrap\">",
"       (-/-)",
"      </span>",
"      mouse shows impaired cell volume regulation in neurons and kidney tubular cells, with deafness, reduced seizure threshold, peripheral neurologic disease, and arterial hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Human KCC3 mutations are associated with agenesis of the corpus callosum and peripheral neuropathy (ACCPN or Anderman Syndrome) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The KCC4",
"      <span class=\"nowrap\">",
"       (-/-)",
"      </span>",
"      mouse exhibits deafness and renal tubular acidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    KCC isoforms 1, 3, and 4 are present in human erythrocytes. K-Cl cotransport mediates extrusion of potassium and chloride from the red cell (",
"    <a class=\"graphic graphic_figure graphicRef62852 \" href=\"mobipreview.htm?3/39/3711\">",
"     figure 1",
"    </a>",
"    ). The functions of this transporter have been studied in several species (sheep, dog and duck) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/30\">",
"     30",
"    </a>",
"    ], in red cells of patients homozygous for hemoglobin C disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/31\">",
"     31",
"    </a>",
"    ], in sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/32\">",
"     32",
"    </a>",
"    ], thalassemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], and in normal human reticulocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most relevant functional properties of K-Cl cotransport are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volume-dependence (with activation by cell swelling)",
"     </li>",
"     <li>",
"      pH-dependence (with optimum pH of 6.7 to 7.2)",
"     </li>",
"     <li>",
"      Inhibition by intracellular magnesium and other divalent cations, including zinc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activation by hydrostatic pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activation by urea and oxidation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activation by positively charged hemoglobin variants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/31,41-43\">",
"       31,41-43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Role in sickle erythrocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocyte dehydration is thought to play an important role in the pathophysiology of the chronic organ damage and acute vasoocclusive events of sickle cell disease. Dehydrated cells have increased cellular hemoglobin (HbS) concentration, which in turn leads to a marked increased in the polymerization of HbS and sickling.",
"   </p>",
"   <p>",
"    The K-Cl cotransport system plays an important role in the pathologic dehydration of sickle red cells, either alone or in conjunction with the calcium-activated potassium (Gardos) channel (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H17#H17\">",
"     \"Specific therapies for sickle cell disease\", section on 'Mechanism of erythrocyte dehydration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is believed that every time sickle erythrocytes are exposed to the renal medullary environment with high urea concentrations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to low pH, they lose potassium, chloride, and water via K-Cl cotransport. Sickle erythrocytes exhibit a marked increase in K-Cl cotransport, an effect that is most likely due to interaction between the relatively positively charged HbS and the cell membrane or the regulatory machinery of the transporter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/41\">",
"     41",
"    </a>",
"    ], since this has also been shown for cells containing HbC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    K-Cl cotransport in normal erythrocytes is inhibited by low oxygen tension and is refractory to stimulation by low pH or urea; in contrast, the activity of the transporter in sickle erythrocytes is independent of oxygen tension and retains the ability to be activated by low pH and urea under hypoxic conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. As a result, the K-Cl cotransporter in sickle erythrocytes can induce significant potassium, chloride, and water loss even at a low pO2 (as occurs, for example, in the renal medulla). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"     \"Renal manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of K-Cl cotransport-induced red cell dehydration is a potential therapeutic strategy for sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary magnesium supplements have been used to increase red cell magnesium content, which impairs K-Cl cotransport and reduces dehydration of sickle cells with minimal side effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/52-54\">",
"       52-54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H16#H16\">",
"       \"Specific therapies for sickle cell disease\", section on 'Reducing intracellular hemoglobin concentration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In one study, addition of a sulfhydryl-reducing agent normalized the sensitivity of K-Cl cotransport activity to urea in sickle cell red cells, mitigating the urea-stimulated volume decrease in sickle cell reticulocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/40\">",
"       40",
"      </a>",
"      ]. This observation suggests that the dysfunctional activity was due, in part, to reversible sulfhydryl oxidation, providing rationale for use of sulfhydryl reducing agents in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Na-H exchanger",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NHE1 sodium-hydrogen exchanger (or antiporter) transports sodium into cells in exchange for hydrogen and accounts for a small fraction of the passive sodium influx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/55\">",
"     55",
"    </a>",
"    ]. In other cell types, but not in human red cells, Na-H exchange mediates the volume regulatory increase following hypertonic shrinkage and regulates cell pH.",
"   </p>",
"   <p>",
"    Na-H exchange is functionally up-regulated in one form of genetically engineered murine spherocytosis, where it probably plays a role in determining the abnormally elevated cell Na content of the red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Na-Mg exchanger",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sodium-magnesium exchanger (or antiporter) plays a crucial role in controlling red cell Mg content by exporting Mg from the erythrocyte in exchange for Na [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/57\">",
"     57",
"    </a>",
"    ]. This exchanger may be involved in generating the abnormally low Mg content observed in sickle erythrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/58\">",
"     58",
"    </a>",
"    ]. The human gene SCL41A1 has been shown to encode for the Na-Mg exchanger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anion exchanger (band 3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protein mediating anion exchange (band 3) in human red cells is encoded by the AE1 gene on human chromosome 17 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/60\">",
"     60",
"    </a>",
"    ]. The 95 kDa human anion exchanger-1 protein (AE1) has two main structural and functional domains: the N-terminal cytoplasmic domain, involved in the interaction with the complex ankyrin, band 4.1, and band 4.2 and with hemoglobin and glycolytic enzymes; and the C-terminal membrane-spanning domain involved in ion transport. Each human red cell contains approximately 1.2 million copies of AE1 per cell.",
"   </p>",
"   <p>",
"    The AE1 anion exchanger, which primarily functions as a chloride-bicarbonate exchanger, provides the basis for the high permeability of the red cells to chloride and bicarbonate ions. Its physiological function to facilitate CO2 transport from tissues to alveoli may be related to its ability to bind deoxyhemoglobin, but not oxyhemoglobin, with high affinity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/61\">",
"     61",
"    </a>",
"    ]. It also plays an important role in defining red cell shape and membrane stability, as shown by the association of genetic defects in band 3 with hereditary spherocytosis and hereditary stomatocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. A comprehensive review of band 3 mutations in erythroid and other tissues is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8841?source=see_link\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although absence of band 3 was thought to be incompatible with life, studies using targeted mutagenesis in mice suggest that complete band 3 deficiency is associated with chronic hemolytic anemia, and increased perinatal death rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/66\">",
"     66",
"    </a>",
"    ]. The absence of band 3 was associated with normal cytoskeletal assembly but the mechanical stability of the red cell was greatly impaired. Band 3 also plays an important role in regulating mitosis in erythropoietic cells, and may be involved in dyserythropoietic disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homozygous mutations in band 3 have been generally believed to be lethal, due to extreme erythrocyte cytoskeletal instability and associated severe hemolytic anemia. However, three homozygous human band 3 mutations have been described, all in association with severe hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Band 3 Coimbra (Val488Met), a variant associated with complete absence of band 3 in erythrocytes. This mutation was found in a newborn with severe hemolysis, hydrops, distal renal tubular acidosis, and nephrocalcinosis, who required chronic blood transfusion and daily bicarbonate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/68,69\">",
"       68,69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Band 3 Neapolis, a T-to-C substitution at the +2 position in the donor splice site of intron 2, resulting in an 88 percent reduction of erythroid band 3, resulting in transfusion-dependent severe hemolytic anemia which markedly improved after splenectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Band 3 Courcouronnes (Ser667Phe), a mutation resulting in a 65 percent reduction of erythroid band 3, associated with transfusion-dependent hemolysis and distal renal tubular acidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Calcium-activated potassium channel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium-activated potassium channel of red cells is also called the \"Gardos\" pathway, since Gardos was the first to report the effect of calcium on potassium permeability of human red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/72\">",
"     72",
"    </a>",
"    ]. The Gardos channel is activated by micromolar concentrations of calcium (k",
"    <sub>",
"     50",
"    </sub>",
"    = 0.3 to 2",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Each human red cell carries approximately 120 &plusmn; 36 channels per cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/73\">",
"     73",
"    </a>",
"    ]. The Gardos channel is inhibited by charybdotoxin and by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    and other imidazole antimycotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The molecular structure of the Gardos channel has been determined. This channel is the prototype of the intermediate conductance calcium-gated potassium channels (IK channels) and is now designated as KCNN4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. No other type of potassium channel has been demonstrated in human erythrocytes.",
"   </p>",
"   <p>",
"    In addition to its role in sickle cell anemia (see below), the Gardos channel appears to play an important role in protecting from lysis erythrocytes affected by cytoskeletal abnormalities, compensating for their reduced surface",
"    <span class=\"nowrap\">",
"     area/volume",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Role in sickle erythrocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gardos channel, as well as the K-Cl cotransporter mentioned above, plays a major role in the dehydration of sickle red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/46\">",
"     46",
"    </a>",
"    ]. Deoxygenation and sickling increase calcium permeability, resulting in activation of the Gardos channel, potassium loss, and dehydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. In vitro studies suggest that the majority of irreversibly sickled cells, which contribute to vasoocclusion, are markedly dehydrated (hyperdense), a process that seems more dependent upon the Gardos channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/46,50\">",
"     46,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that the antifungal drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    is a specific inhibitor of the Gardos channel has provided the opportunity for testing the physiologic and pathophysiologic role of this pathway in vivo. The efficacy of this drug has been demonstrated by studies in transgenic mice and patients with sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. The potential clinical efficacy of this approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H20#H20\">",
"     \"Specific therapies for sickle cell disease\", section on 'Clotrimazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Modulation of the Gardos channel by arginine and potentially by nitric oxide (NO) has been demonstrated in transgenic sickle cell mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/85\">",
"     85",
"    </a>",
"    ]. Chemokines and endothelins have also been shown to activate the Gardos channel in vitro and may play a role in the dehydration of sickle erythrocytes in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Voltage-gated channel",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the membrane potential of human red cells becomes inside-positive, a voltage-activated movement of sodium, potassium, and calcium can be demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/88\">",
"     88",
"    </a>",
"    ]. This voltage-activated, nonselective cation movement takes place via the Na-K-ATPase pump, since it can be demonstrated in proteoliposomes containing reconstituted shark ATPase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Water channels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water movement passively follows that of cations and anions or is induced by changes in tonicity of the environment surrounding the red cells. The transport of water across the red cell membrane can occur at a much faster rate via water channels. The red cell integral membrane protein CHIP28 has been shown to mediate water transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/90\">",
"     90",
"    </a>",
"    ]. This protein is now called aquaporin-1 and is the prototype of the aquaporin family of water transporters (",
"    <a class=\"graphic graphic_figure graphicRef62852 \" href=\"mobipreview.htm?3/39/3711\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/2\">",
"     2",
"    </a>",
"    ]. The Colton blood group antigen polymorphism is a single amino acid substitution in an extracellular domain of aquaporin-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=see_link&amp;anchor=H68#H68\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Colton blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few families have been identified in which members are deficient in aquaporin-1 and are Colton null [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Surprisingly, affected patients are clinically normal except for a modest reduction in urinary concentrating ability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Red cell aging, ion transport, and content",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell aging is associated with a progressive increase in cell density due to loss of K+ and water. However, in the terminal phase of the red cell lifespan, dense erythrocytes gain a substantial amount of Na+ and swell. Using density gradient centrifugation, they can be found in the lightest fraction, together with the reticulocytes. This stage most likely represents a terminal phase immediately preceding the removal of both normal and sickle erythrocytes from the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37224/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H676392\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The water, cation, and anion contents of red cells are continuously regulated by the activity and interactions of several ion transport systems (",
"    <a class=\"graphic graphic_figure graphicRef62852 \" href=\"mobipreview.htm?3/39/3711\">",
"     figure 1",
"    </a>",
"    ). The importance of these systems is indicated by the various diseases occurring when red cell ion transport is impaired (",
"    <a class=\"graphic graphic_table graphicRef80358 \" href=\"mobipreview.htm?12/39/12923\">",
"     table 1",
"    </a>",
"    ). The following systems are involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Water content",
"      </strong>",
"      : Water can move across the red cell membrane by passive diffusion and also via the specific water channel aquaporin-1. These allow the red cell to be in osmotic equilibrium with the plasma. As a result, the water content of the human red cell is determined by the intracellular sodium, potassium, and Cl content and the osmolality of the plasma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Water content'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Water channels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Cation content",
"      </strong>",
"      : The low sodium, low calcium, and high potassium milieu of the red cell is maintained by the energy-driven Na-K-ATPase and Ca-ATPase pumps, and by the passive gradient-driven Na-K-CL transport, K-Cl cotransport, Na-H exchanger, Na-Mg exchanger, and Ca-activated potassium (Gardos) channels.",
"     </li>",
"     <li>",
"      <strong>",
"       Anion content",
"      </strong>",
"      : The AE1 anion exchanger (band 3) primarily functions as a chloride-bicarbonate exchanger. Its physiological function to facilitate CO",
"      <sub>",
"       2",
"      </sub>",
"      transport from tissues to alveoli may be related to its ability to bind deoxyhemoglobin, but not oxyhemoglobin, with high affinity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anion content'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Anion exchanger (band 3)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/1\">",
"      Gallagher PG. Disorders of red cell volume regulation. Curr Opin Hematol 2013; 20:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/2\">",
"      Agre P, King LS, Yasui M, et al. Aquaporin water channels--from atomic structure to clinical medicine. J Physiol 2002; 542:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/3\">",
"      Shull GE, Schwartz A, Lingrel JB. Amino-acid sequence of the catalytic subunit of the (Na+ + K+)ATPase deduced from a complementary DNA. Nature 1985; 316:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/4\">",
"      Martin-Vasallo P, Dackowski W, Emanuel JR, Levenson R. Identification of a putative isoform of the Na,K-ATPase beta subunit. Primary structure and tissue-specific expression. J Biol Chem 1989; 264:4613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/5\">",
"      Joiner CH, Lauf PK. Ouabain binding and potassium transport in young and old populations of human red cells. Membr Biochem 1978; 1:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/6\">",
"      TOSTESON DC, HOFFMAN JF. Regulation of cell volume by active cation transport in high and low potassium sheep red cells. J Gen Physiol 1960; 44:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/7\">",
"      Halperin JA, Brugnara C, Kopin AS, et al. Properties of the Na+-K+ pump in human red cells with increased number of pump sites. J Clin Invest 1987; 80:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/8\">",
"      De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/9\">",
"      Segall L, Scanzano R, Kaunisto MA, et al. Kinetic alterations due to a missense mutation in the Na,K-ATPase alpha2 subunit cause familial hemiplegic migraine type 2. J Biol Chem 2004; 279:43692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/10\">",
"      de Carvalho Aguiar P, Sweadner KJ, Penniston JT, et al. Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 2004; 43:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/11\">",
"      Benarroch EE. Na+, K+-ATPase: functions in the nervous system and involvement in neurologic disease. Neurology 2011; 76:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/12\">",
"      Strehler EE, James P, Fischer R, et al. Peptide sequence analysis and molecular cloning reveal two calcium pump isoforms in the human erythrocyte membrane. J Biol Chem 1990; 265:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/13\">",
"      Etzion Z, Tiffert T, Bookchin RM, Lew VL. Effects of deoxygenation on active and passive Ca2+ transport and on the cytoplasmic Ca2+ levels of sickle cell anemia red cells. J Clin Invest 1993; 92:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/14\">",
"      Lew VL, Daw N, Perdomo D, et al. Distribution of plasma membrane Ca2+ pump activity in normal human red blood cells. Blood 2003; 102:4206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/15\">",
"      Lew VL, Daw N, Etzion Z, et al. Effects of age-dependent membrane transport changes on the homeostasis of senescent human red blood cells. Blood 2007; 110:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/16\">",
"      Wiley JS, Cooper RA. A furosemide-sensitive cotransport of sodium plus potassium in the human red cell. J Clin Invest 1974; 53:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/17\">",
"      Haas M. The Na-K-Cl cotransporters. Am J Physiol 1994; 267:C869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/18\">",
"      Xu JC, Lytle C, Zhu TT, et al. Molecular cloning and functional expression of the bumetanide-sensitive Na-K-Cl cotransporter. Proc Natl Acad Sci U S A 1994; 91:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/19\">",
"      Gamba G, Miyanoshita A, Lombardi M, et al. Molecular cloning, primary structure, and characterization of two members of the mammalian electroneutral sodium-(potassium)-chloride cotransporter family expressed in kidney. J Biol Chem 1994; 269:17713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/20\">",
"      Delpire E, Rauchman MI, Beier DR, et al. Molecular cloning and chromosome localization of a putative basolateral Na(+)-K(+)-2Cl- cotransporter from mouse inner medullary collecting duct (mIMCD-3) cells. J Biol Chem 1994; 269:25677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/21\">",
"      Brugnara C, Canessa M, Cusi D, Tosteson DC. Furosemide-sensitive Na and K fluxes in human red cells. Net uphill Na extrusion and equilibrium properties. J Gen Physiol 1986; 87:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/22\">",
"      Gillen CM, Brill S, Payne JA, Forbush B 3rd. Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human. A new member of the cation-chloride cotransporter family. J Biol Chem 1996; 271:16237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/23\">",
"      Payne JA, Stevenson TJ, Donaldson LF. Molecular characterization of a putative K-Cl cotransporter in rat brain. A neuronal-specific isoform. J Biol Chem 1996; 271:16245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/24\">",
"      Race JE, Makhlouf FN, Logue PJ, et al. Molecular cloning and functional characterization of KCC3, a new K-Cl cotransporter. Am J Physiol 1999; 277:C1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/25\">",
"      Mercado A, Song L, Vazquez N, et al. Functional comparison of the K+-Cl- cotransporters KCC1 and KCC4. J Biol Chem 2000; 275:30326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/26\">",
"      H&uuml;bner CA, Stein V, Hermans-Borgmeyer I, et al. Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early synaptic inhibition. Neuron 2001; 30:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/27\">",
"      Boettger T, Rust MB, Maier H, et al. Loss of K-Cl co-transporter KCC3 causes deafness, neurodegeneration and reduced seizure threshold. EMBO J 2003; 22:5422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/28\">",
"      Howard HC, Mount DB, Rochefort D, et al. The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum. Nat Genet 2002; 32:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/29\">",
"      Boettger T, H&uuml;bner CA, Maier H, et al. Deafness and renal tubular acidosis in mice lacking the K-Cl co-transporter Kcc4. Nature 2002; 416:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/30\">",
"      Lauf PK, Bauer J, Adragna NC, et al. Erythrocyte K-Cl cotransport: properties and regulation. Am J Physiol 1992; 263:C917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/31\">",
"      Brugnara C, Kopin AS, Bunn HF, Tosteson DC. Regulation of cation content and cell volume in hemoglobin erythrocytes from patients with homozygous hemoglobin C disease. J Clin Invest 1985; 75:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/32\">",
"      Brugnara C, Bunn HF, Tosteson DC. Regulation of erythrocyte cation and water content in sickle cell anemia. Science 1986; 232:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/33\">",
"      De Franceschi L, Ronzoni L, Cappellini MD, et al. K-CL co-transport plays an important role in normal and beta thalassemic erythropoiesis. Haematologica 2007; 92:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/34\">",
"      De Franceschi L, Cappellini MD, Graziadei G, et al. The effect of dietary magnesium supplementation on the cellular abnormalities of erythrocytes in patients with beta thalassemia intermedia. Haematologica 1998; 83:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/35\">",
"      Brugnara C, Tosteson DC. Cell volume, K transport, and cell density in human erythrocytes. Am J Physiol 1987; 252:C269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/36\">",
"      Brugnara C, Tosteson DC. Inhibition of K transport by divalent cations in sickle erythrocytes. Blood 1987; 70:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/37\">",
"      Godart H, Ellory JC. KCl cotransport activation in human erythrocytes by high hydrostatic pressure. J Physiol 1996; 491 ( Pt 2):423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/38\">",
"      Kaji DM, Gasson C. Urea activation of K-Cl transport in human erythrocytes. Am J Physiol 1995; 268:C1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/39\">",
"      Olivieri O, Bonollo M, Friso S, et al. Activation of K+/Cl- cotransport in human erythrocytes exposed to oxidative agents. Biochim Biophys Acta 1993; 1176:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/40\">",
"      Joiner CH, Rettig RK, Jiang M, et al. Urea stimulation of KCl cotransport induces abnormal volume reduction in sickle reticulocytes. Blood 2007; 109:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/41\">",
"      Olivieri O, Vitoux D, Galacteros F, et al. Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes. Blood 1992; 79:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/42\">",
"      Nagel RL, Krishnamoorthy R, Fattoum S, et al. The erythrocyte effects of haemoglobin O(ARAB). Br J Haematol 1999; 107:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/43\">",
"      Romero JR, Suzuka SM, Nagel RL, Fabry ME. Expression of HbC and HbS, but not HbA, results in activation of K-Cl cotransport activity in transgenic mouse red cells. Blood 2004; 103:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/44\">",
"      Joiner CH. Cation transport and volume regulation in sickle red blood cells. Am J Physiol 1993; 264:C251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/45\">",
"      Franco RS, Palascak M, Thompson H, et al. Dehydration of transferrin receptor-positive sickle reticulocytes during continuous or cyclic deoxygenation: role of KCl cotransport and extracellular calcium. Blood 1996; 88:4359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/46\">",
"      McGoron AJ, Joiner CH, Palascak MB, et al. Dehydration of mature and immature sickle red blood cells during fast oxygenation/deoxygenation cycles: role of KCl cotransport and extracellular calcium. Blood 2000; 95:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/47\">",
"      Franco RS, Thompson H, Palascak M, Joiner CH. The formation of transferrin receptor-positive sickle reticulocytes with intermediate density is not determined by fetal hemoglobin content. Blood 1997; 90:3195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/48\">",
"      Gibson JS, Speake PF, Ellory JC. Differential oxygen sensitivity of the K+-Cl- cotransporter in normal and sickle human red blood cells. J Physiol 1998; 511 ( Pt 1):225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/49\">",
"      Culliford SJ, Ellory JC, Gibson JS, Speake PF. Effects of urea and oxygen tension on K flux in sickle cells. Pflugers Arch 1998; 435:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/50\">",
"      Lew VL, Bookchin RM. Ion transport pathology in the mechanism of sickle cell dehydration. Physiol Rev 2005; 85:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/51\">",
"      Rust MB, Alper SL, Rudhard Y, et al. Disruption of erythroid K-Cl cotransporters alters erythrocyte volume and partially rescues erythrocyte dehydration in SAD mice. J Clin Invest 2007; 117:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/52\">",
"      De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997; 100:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/53\">",
"      De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol 2000; 108:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/54\">",
"      Hankins JS, Wynn LW, Brugnara C, et al. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol 2008; 140:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/55\">",
"      Morgan K, Canessa M. Interactions of external and internal H+ and Na+ with Na+/Na+ and Na+/H+ exchange of rabbit red cells: evidence for a common pathway. J Membr Biol 1990; 118:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/56\">",
"      De Franceschi L, Rivera A, Bize I, et al. Murine Spherocytosis: Evidence for a Functional Interaction between Protein 4.1 and Na/H Exchange and for a \"Protective\" Role of the Gardos Channel Against Hemolysis (abstract). Blood 2004; 104:578a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/57\">",
"      F&eacute;ray JC, Garay R. An Na+-stimulated Mg2+-transport system in human red blood cells. Biochim Biophys Acta 1986; 856:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/58\">",
"      Rivera A, Ferreira A, Bertoni D, et al. Abnormal regulation of Mg2+ transport via Na/Mg exchanger in sickle erythrocytes. Blood 2005; 105:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/59\">",
"      Kolisek M, Nestler A, Vormann J, Schweigel-R&ouml;ntgen M. Human gene SLC41A1 encodes for the Na+/Mg&sup2;+ exchanger. Am J Physiol Cell Physiol 2012; 302:C318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/60\">",
"      Alper SL. The band 3-related anion exchanger (AE) gene family. Annu Rev Physiol 1991; 53:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/61\">",
"      Chu H, Breite A, Ciraolo P, et al. Characterization of the deoxyhemoglobin binding site on human erythrocyte band 3: implications for O2 regulation of erythrocyte properties. Blood 2008; 111:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/62\">",
"      Jarolim P, Rubin HL, Brabec V, et al. Mutations of conserved arginines in the membrane domain of erythroid band 3 lead to a decrease in membrane-associated band 3 and to the phenotype of hereditary spherocytosis. Blood 1995; 85:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/63\">",
"      Bruce LJ, Robinson HC, Guizouarn H, et al. Monovalent cation leaks in human red cells caused by single amino-acid substitutions in the transport domain of the band 3 chloride-bicarbonate exchanger, AE1. Nat Genet 2005; 37:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/64\">",
"      Guizouarn H, Martial S, Gabillat N, Borgese F. Point mutations involved in red cell stomatocytosis convert the electroneutral anion exchanger 1 to a nonselective cation conductance. Blood 2007; 110:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/65\">",
"      Alper SL. Molecular physiology and genetics of Na+-independent SLC4 anion exchangers. J Exp Biol 2009; 212:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/66\">",
"      Peters LL, Shivdasani RA, Liu SC, et al. Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton. Cell 1996; 86:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/67\">",
"      Paw BH, Davidson AJ, Zhou Y, et al. Cell-specific mitotic defect and dyserythropoiesis associated with erythroid band 3 deficiency. Nat Genet 2003; 34:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/68\">",
"      Ribeiro ML, Alloisio N, Almeida H, et al. Severe hereditary spherocytosis and distal renal tubular acidosis associated with the total absence of band 3. Blood 2000; 96:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/69\">",
"      Cordat E. Unraveling trafficking of the kidney anion exchanger 1 in polarized MDCK epithelial cells. Biochem Cell Biol 2006; 84:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/70\">",
"      Perrotta S, Borriello A, Scaloni A, et al. The N-terminal 11 amino acids of human erythrocyte band 3 are critical for aldolase binding and protein phosphorylation: implications for band 3 function. Blood 2005; 106:4359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/71\">",
"      Toye AM, Williamson RC, Khanfar M, et al. Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A. Blood 2008; 111:5380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/72\">",
"      GARDOS G. The function of calcium in the potassium permeability of human erythrocytes. Biochim Biophys Acta 1958; 30:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/73\">",
"      Brugnara C, De Franceschi L, Alper SL. Ca(2+)-activated K+ transport in erythrocytes. Comparison of binding and transport inhibition by scorpion toxins. J Biol Chem 1993; 268:8760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/74\">",
"      Stocker JW, De Franceschi L, McNaughton-Smith GA, et al. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 2003; 101:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/75\">",
"      Ishii TM, Silvia C, Hirschberg B, et al. A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci U S A 1997; 94:11651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/76\">",
"      Vandorpe DH, Shmukler BE, Jiang L, et al. cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem 1998; 273:21542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/77\">",
"      Hoffman JF, Joiner W, Nehrke K, et al. The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells. Proc Natl Acad Sci U S A 2003; 100:7366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/78\">",
"      De Franceschi L, Rivera A, Fleming MD, et al. Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis. Blood 2005; 106:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/79\">",
"      Bookchin RM, Ortiz OE, Lew VL. Evidence for a direct reticulocyte origin of dense red cells in sickle cell anemia. J Clin Invest 1991; 87:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/80\">",
"      Lew VL, Ortiz OE, Bookchin RM. Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability. J Clin Invest 1997; 99:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/81\">",
"      Lew VL, Etzion Z, Bookchin RM. Dehydration response of sickle cells to sickling-induced Ca(++) permeabilization. Blood 2002; 99:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/82\">",
"      De Franceschi L, Saadane N, Trudel M, et al. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J Clin Invest 1994; 93:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/83\">",
"      Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996; 97:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/84\">",
"      Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008; 111:3991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/85\">",
"      Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 2002; 99:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/86\">",
"      Rivera A, Rotter MA, Brugnara C. Endothelins activate Ca(2+)-gated K(+) channels via endothelin B receptors in CD-1 mouse erythrocytes. Am J Physiol 1999; 277:C746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/87\">",
"      Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood 2002; 99:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/88\">",
"      Halperin JA, Brugnara C, Tosteson MT, et al. Voltage-activated cation transport in human erythrocytes. Am J Physiol 1989; 257:C986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/89\">",
"      Halperin JA, Cornelius F. A voltage-activated cation transport pathway associated with the sodium pump. Biochim Biophys Acta 1991; 1070:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/90\">",
"      Preston GM, Carroll TP, Guggino WB, Agre P. Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein. Science 1992; 256:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/91\">",
"      Smith BL, Preston GM, Spring FA, et al. Human red cell aquaporin CHIP. I. Molecular characterization of ABH and Colton blood group antigens. J Clin Invest 1994; 94:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/92\">",
"      Preston GM, Smith BL, Zeidel ML, et al. Mutations in aquaporin-1 in phenotypically normal humans without functional CHIP water channels. Science 1994; 265:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/93\">",
"      King LS, Choi M, Fernandez PC, et al. Defective urinary-concentrating ability due to a complete deficiency of aquaporin-1. N Engl J Med 2001; 345:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/94\">",
"      Bookchin RM, Etzion Z, Sorette M, et al. Identification and characterization of a newly recognized population of high-Na+, low-K+, low-density sickle and normal red cells. Proc Natl Acad Sci U S A 2000; 97:8045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37224/abstract/95\">",
"      Holtzclaw JD, Jiang M, Yasin Z, et al. Rehydration of high-density sickle erythrocytes in vitro. Blood 2002; 100:3017.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7165 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37224=[""].join("\n");
var outline_f36_22_37224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H676392\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Cation content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anion content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Water content",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ENERGY-DRIVEN SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      N-K-ATPase pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ca-ATPase pump",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PASSIVE GRADIENT-DRIVEN SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Na-K-Cl cotransport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      K-Cl cotransport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Role in sickle erythrocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Na-H exchanger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Na-Mg exchanger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anion exchanger (band 3)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Calcium-activated potassium channel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Role in sickle erythrocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Voltage-gated channel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Water channels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Red cell aging, ion transport, and content",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H676392\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7165\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7165|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/39/3711\" title=\"figure 1\">",
"      Red cell ion transport mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7165|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/39/12923\" title=\"table 1\">",
"      Abnormal red cell ion transport",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_22_37225="Chorioangioma";
var content_f36_22_37225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Chorioangioma with multiple small vascular channels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37225=[""].join("\n");
var outline_f36_22_37225=null;
var title_f36_22_37226="Complications of cranial irradiation";
var content_f36_22_37226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of cranial irradiation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37226/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37226/contributors\">",
"     Ari Ballonoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37226/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37226/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/22/37226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/22/37226/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/22/37226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial irradiation is used to treat patients with primary or metastatic brain tumors and as prophylaxis for selected patients at high risk of neoplastic involvement of the nervous system. A full understanding of the potential consequences associated with cranial irradiation is needed both to manage potential complications and to properly counsel patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    families prior to treatment.",
"   </p>",
"   <p>",
"    The primary factors influencing the likelihood of developing complications include the volume of normal brain tissue treated, the total radiation dose, and the fractionation schedule. The likelihood of brain damage also increases in the young (ie, &lt;5 years old) and the elderly. Furthermore, the use of concurrent or sequential chemotherapy can significantly affect the incidence and severity of radiation-induced toxicity. In addition, the underlying tumor often can impair neurologic function, making it difficult to assess accurately the separate effect of radiation. Finally, genetic factors may make certain individuals more susceptible to otherwise safe doses of radiation. For example, a study of 15 families with radiation-induced meningiomas after treatment for tinea capitis identified several genes as potential risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/1\">",
"     1",
"    </a>",
"    ]. Other genetic markers have been found to enhance susceptibility when specific organs are irradiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complications of radiation therapy (RT) are usually divided into acute effects that can occur during the course of radiation, early-delayed effects that appear two to four months after radiation, and late effects that can develop more than 90 days after the initiation of RT. The Radiation Therapy Oncology Group (RTOG) has established specific grading criteria for acute and delayed toxicities (",
"    <a class=\"graphic graphic_table graphicRef64833 \" href=\"mobipreview.htm?23/32/24075\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73580 \" href=\"mobipreview.htm?9/0/9227\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications that might occur many months or even years following cranial irradiation are generally not important as a consideration for patients with brain metastases or grade IV primary brain tumors, where a median survival in the range of 6 to 15 months is expected. Late effects are a more important consideration for patients with a much longer life expectancy (eg, low-grade glioma and primary CNS lymphoma patients or pediatric patients with acute lymphocytic leukemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The distinction between early and late complications is also important since acute and early-delayed complications are usually reversible while late reactions often are not.",
"   </p>",
"   <p>",
"    Both the acute and late complications of fractionated cranial irradiation will be reviewed here. Complications of spinal cord and peripheral nerve irradiation and complications of single-fraction cranial radiosurgery are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=see_link\">",
"     \"Complications of spinal cord irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=see_link\">",
"     \"Complications of peripheral nerve irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2566?source=see_link\">",
"     \"Complications of cranial stereotactic radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of radiation can be divided into the effects on the vasculature of the brain as well as the direct effects on glial cells and their precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/6\">",
"     6",
"    </a>",
"    ]. Inflammation and blood-brain barrier disruption, induced by the radiation, may also cause cellular damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In experimental animals, endothelial damage probably leading to blood- brain barrier disruption occurs within the first 24 hours after a large single dose of radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/8\">",
"     8",
"    </a>",
"    ]. The mechanism is not known, but endothelial apoptosis appears to play a role. Late effects of radiation on brain vasculature lead to telangiectasias, microvascular dilatation, and thickening and hyalinization of the vessel wall with fibrinoid necrosis. As a result, ischemic strokes or brain hemorrhage may occur years after prophylactic radiation to the brain for treatment of leukemia (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Cerebrovascular effects'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing evidence in experimental animals suggests that radiation impairs hippocampal neurogenesis, leading to a decrease in the number of mature neurons in areas subserving memory (ie, hippocampus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/7\">",
"     7",
"    </a>",
"    ]. Such changes could lead to cognitive defects, particularly short-term memory, in the absence of identifiable changes on MRI (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Neurocognitive effects in adults'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Radiation can also have direct cytotoxic effect upon glial cells and their progenitors. Apoptosis of mature oligodendrocytes, the cells that produce myelin, may be responsible for the demyelination that probably underlies early-delayed encephalopathy (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Somnolence and the somnolence syndrome'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/10\">",
"     10",
"    </a>",
"    ]. Radiation also damages O-2A progenitor cells, the precursor of both oligodendrocytes and type II astrocytes. Such damage, in combination with vascular damage, may cause late radiation necrosis.",
"   </p>",
"   <p>",
"    Radiation induces an inflammatory response characterized by an increase in activated microglia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/7\">",
"     7",
"    </a>",
"    ] and by induction of cytokine genes, such as tumor necrosis factor alpha and interleukin-1 beta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/8\">",
"     8",
"    </a>",
"    ]. The role of this inflammatory response in vascular and cellular damage is unknown.",
"   </p>",
"   <p>",
"    Finally, some evidence suggests that damage to neural stem cells found in the subventricular zone and dentate gyrus in the hippocampus may play a role in preventing recovery from radiation damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/11\">",
"     11",
"    </a>",
"    ]. Intensity-modulated radiation therapy has been suggested as a way to spare neural stem cells when treating brain tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute and late side effects of cranial irradiation are a function of the total dose of radiation, the fraction size, and the volume of brain irradiated. The relationship of these factors to specific toxicities are discussed below; the general issues involved in relating these parameters to the likelihood of radiation necrosis, cognitive impairment and other neurotoxicities are reviewed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute encephalopathy may occur when radiation fractions &gt;3 Gy are administered to a large brain volume, particularly in patients with elevated intracranial pressure (ICP). Symptoms include severe headache, nausea, drowsiness, and focal neurologic deficits and fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/14\">",
"     14",
"    </a>",
"    ]; in extremely rare cases, death may occur due to cerebral herniation. This effect is thought to be due to disruption of the blood-brain barrier leading to cerebral edema. Acute encephalopathy is generally most severe following the first radiation dose and gradually lessens in severity thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With a better understanding of the relationship between dose, schedule, and toxicity, acute encephalopathy is rare with modern treatment techniques. However, in a 1970 study, patients received 10 Gy of whole brain radiation therapy (WBRT) in one fraction, and 7 percent of the patients died within 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/15\">",
"     15",
"    </a>",
"    ]. To avoid this catastrophic complication, WBRT is generally administered in fractions of 3 Gy or less; with this schedule the risk of severe acute encephalopathy is negligible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transient worsening of pretreatment symptoms can occur early in the course of radiation, probably as a result of transient mild cerebral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/16\">",
"     16",
"    </a>",
"    ]. Corticosteroids can lessen the radiation-induced blood-brain-barrier disruptions and improve the symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with recognized significant pretreatment cerebral edema should begin oral or parenteral corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    8 to 16 mg daily) prior to initiating radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/18\">",
"     18",
"    </a>",
"    ]. Maintaining the dose for the first two weeks of RT can prevent clinical deterioration due to transiently worsened peritumoral edema. However, a short-term increase in corticosteroid dose may be warranted if symptoms are severe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and vomiting are uncommon side effects of cranial radiation. Antiemetics or corticosteroids are used to prevent or mitigate symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3847?source=see_link\">",
"     \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiation dermatitis and alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total or partial alopecia is extremely common after cranial irradiation and may be permanent with higher total doses. Alopecia occurs only where the radiation beams traverse the scalp, so patients receiving partial brain irradiation may develop patchy alopecia. The severity and permanence of alopecia is directly related to dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation dermatitis is usually mild and may be treated with soothing moisturizing ointments. Areas of skin receiving particularly high doses may demonstrate dry or moist desquamation that requires more intensive bacteriostatic topical treatments. In patients who have recently begun",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    anticonvulsant therapy, an unusually severe skin reaction or one that extends beyond the RT fields might be the first sign of a developing Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/20\">",
"     20",
"    </a>",
"    ]. The anticonvulsant should be stopped immediately. Otitis externa is common if the ear is within the radiation treatment field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hearing problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serous otitis media rarely may occur acutely, resulting in a conductive hearing loss, which occasionally requires myringotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Myelosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant myelosuppression is unlikely to occur as a result of cranial irradiation. However, myelosuppression may be seen in patients receiving simultaneous treatment to the spine (craniospinal irradiation), which involves treatment to a large volume of bone marrow. Myelosuppression may also be seen in patients receiving concomitant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mucositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngeal mucositis, characterized by local irritation, erythema, swelling, and pain, is also uncommon unless patients are receiving craniospinal irradiation. During craniospinal irradiation, the spinal fields exit through the oropharynx and mediastinum causing oropharyngeal and esophageal mucositis, respectively. Such mucositis often occurs after about 25 to 30 Gy in conventional fractionation and usually resolves about two to four weeks after radiation is completed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114056038\">",
"    <span class=\"h2\">",
"     Parotitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute parotitis and symptomatic or asymptomatic hyperamylasemia is an uncommon complication of whole brain radiation therapy; it occurs when the lower end of the radiation portal encompasses the parotid gland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/22\">",
"     22",
"    </a>",
"    ]. The acute symptoms include fever, pain, swelling and tenderness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EARLY-DELAYED REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common early-delayed reactions to cranial radiation include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     MRI contrast enhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to well-defined clinical syndromes, the routine use of cranial magnetic resonance imaging (MRI) has led to the identification of posttreatment asymptomatic MRI contrast enhancement, which is a transient abnormality but can be hard to distinguish from tumor progression.",
"   </p>",
"   <p>",
"    This phenomenon has been termed pseudoprogression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of recurrent malignant gliomas\", section on 'Early progression versus pseudoprogression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Somnolence and the somnolence syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study of 68 evaluable patients treated for primary brain tumors, fatigue was scored according to the Littman somnolence scale. Most patients were treated for glioblastoma to a dose of 55 Gy in 30 fractions to partial brain fields; concurrent chemotherapy was not given. Ninety percent experienced at least grade 1 symptoms (disturbance with some tiredness, but activity not curtailed), and approximately half experienced mild to moderate symptoms (decreased activity and increased tiredness, sleeping much of the day, most activities curtailed). A higher grade of somnolence was rare (1 percent). The symptoms typically peaked approximately six weeks after the radiotherapy and then slowly resolved over the next several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/23\">",
"     23",
"    </a>",
"    ]. Although no clinical trials exist, anecdotal evidence suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The somnolence syndrome is characterized by extreme sleepiness in conjunction with signs of increased intracranial pressure (eg, headache, nausea, vomiting, anorexia, and irritability) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/25\">",
"     25",
"    </a>",
"    ]. The somnolence syndrome is more common in children than in adults, with the onset typically occurring one to six months after prophylactic cranial irradiation for acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The syndrome is occasionally accompanied by transient recrudescence of a previously resolved neurologic deficit. Brain MRI may show non-specific white matter hyperintensity.",
"   </p>",
"   <p>",
"    The somnolence syndrome usually resolves spontaneously within two to three weeks. Corticosteroid treatment may provide symptomatic relief and reduce the incidence of this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, the routine use of corticosteroids for treatment of somnolence syndrome is not widely recommended. Patients with this syndrome are not at increased risk for other late effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Transient focal neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients undergo a delayed transient worsening of symptoms that can suggest tumor progression, with headache",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrence of pretreatment neurologic symptoms and signs. The likely etiology is a combination of tumor response and peritumoral edema or demyelination; corresponding imaging changes can include focally increased enhancement as a result of blood-brain barrier disruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/30\">",
"     30",
"    </a>",
"    ]. A study of 20 patients with recurrent glioma and 15 patients with radiation injury after treatment of glioma confirmed by histologic examination indicates that diffusion tension imaging may help distinguish radiation injury from recurrent tumor. When either the apparent diffusion coefficient (ADC) ratio was &lt;1.65",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the fractional anisotropy (FA) ratio &gt;0.36 in the contrast-enhanced area, a recurrent tumor was likely. Out of 35 patients, three with recurrent tumor and two with radiation injury were incorrectly classified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reversible defects in memory also occur and do not necessarily predict long-term impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In a prospective study of 10 patients with low-grade tumors treated with limited field radiation in doses from 46 to 63 Gy, a transient decline in verbal long-term memory was observed 1.5 months after completion of RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/32\">",
"     32",
"    </a>",
"    ]. This deficit was reversible, however, and patients had returned to baseline by one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LATE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, late reactions are observed more than 90 days after the start of cranial radiation. The Radiation Therapy Oncology Group (RTOG) has established grading criteria specifically for these delayed toxicities (",
"    <a class=\"graphic graphic_table graphicRef73580 \" href=\"mobipreview.htm?9/0/9227\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/34\">",
"     34",
"    </a>",
"    ]. Unlike early-delayed reactions that are usually reversible, late reactions are generally irreversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiation necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation necrosis is a serious complication that typically develops one to three years after radiation. Symptoms produced by localized brain necrosis depend upon the location of the lesion and can include focal neurologic deficits or more generalized signs and symptoms of increased intracranial pressure.",
"   </p>",
"   <p>",
"    Radiation necrosis is caused by vascular endothelial cell damage, resulting in fibrinoid necrosis of small arterial vessels. Occlusion of these vessels results in focal coagulative necrosis and demyelination of the overlying brain parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The disruption of the blood-brain barrier (as characterized by gadolinium) may be mediated in part by vascular endothelial growth factor (VEGF) that is released in response to hypoxia.",
"   </p>",
"   <p>",
"    Evidence supporting the role of VEGF in the pathogenesis of radiation necrosis comes from the observation that the imaging abnormalities seen with radiation necrosis may be reversed in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody that binds VEGF. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Radiation necrosis typically develops at or adjacent to the original site of tumor, the location that received the highest radiation dose. Rarely, radiation necrosis develops in part of the normal brain parenchyma that was included in the treatment field of a tumor outside the brain, such as temporal lobe necrosis in a patient treated for a nasopharyngeal cancer. In this setting, necrosis is typically manifested by new focal neurologic signs, and imaging studies such as CT or MRI may show an enhancing mass with edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8250?source=see_link\">",
"     \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation necrosis is uncommon with doses of 60 Gy or less using conventional fractionation. The dose that causes a 5 percent risk of focal radionecrosis using conventional fractionation is usually estimated to be in the range of 55 to 60 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Radionecrosis is more likely to occur when high doses per fraction are administered and perhaps with subsequent chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating recurrent tumor from radiation necrosis can be very difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/40\">",
"     40",
"    </a>",
"    ]. MRI typically shows a contrast-enhancing mass with white matter changes and edema within or immediately adjacent to the site of the original tumor, the location which received the highest dose of radiation.",
"   </p>",
"   <p>",
"    Other imaging modalities may occasionally be helpful. Increased cerebral blood volume on perfusion-weighted MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/41\">",
"     41",
"    </a>",
"    ], and increased uptake with FDG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/42-47\">",
"     42-47",
"    </a>",
"    ], methionine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/48\">",
"     48",
"    </a>",
"    ], or thallium chloride-201 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/49\">",
"     49",
"    </a>",
"    ] PET all suggest tumor. In contrast, a high lipid peak on magnetic resonance spectroscopy suggests necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/50-55\">",
"     50-55",
"    </a>",
"    ]. However, biopsy of the suspicious lesion is often needed for a definitive diagnosis particularly because the lesion is often a combination of tumor and necrosis. Diffusion tension imaging may also be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Transient focal neurologic symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical decompression of any radionecrosis-related mass effect can provide helpful palliative effect. Corticosteroids usually produce prompt symptomatic improvement, and symptoms of cerebral edema can resolve with conservative management.",
"   </p>",
"   <p>",
"    Case reports and a randomized trial indicate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    may be useful in selected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. In a double-blind trial, 14 patients with biopsy or radiologically confirmed cerebral radiation necrosis were randomly assigned to bevacizumab&nbsp;(7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for four cycles at three week intervals) or a saline placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/59\">",
"     59",
"    </a>",
"    ]. All patients assigned to bevacizumab had improvement in neurologic symptoms or signs and responded based upon MRI criteria. No responses were seen in those initially treated with placebo, but all patients who progressed on placebo did respond to bevacizumab&nbsp;during treatment crossover.",
"   </p>",
"   <p>",
"    Another case report found that patients might respond to retreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    when symptoms of radiation necrosis recurred after bevacizumab was discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/60\">",
"     60",
"    </a>",
"    ]. However, in another case report, use of bevacizumab appeared to be associated with worsening of clinical symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/61\">",
"     61",
"    </a>",
"    ]. Additional studies will be required to determine the role of bevacizumab in the management of radiation necrosis.",
"   </p>",
"   <p>",
"    Therapeutic anticoagulation and hyperbaric oxygen therapy have also been reported to provide benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/62-64\">",
"     62-64",
"    </a>",
"    ], but their efficacy has not been established. Hyperbaric oxygen treatment was reported to have improved neuropsychological performance in 10 long-term brain tumor survivors who had received both surgery and radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diffuse white matter injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-specific diffuse white matter changes can be seen on MRI in nearly all patients receiving doses over 55 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/40\">",
"     40",
"    </a>",
"    ]. Most patients are asymptomatic, at least initially, but the incidence and severity of symptoms appears to correlate with the severity of radiographic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leukoencephalopathy, the clinical syndrome associated with these radiographic changes, was first described in children receiving prophylactic cranial irradiation and systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/67\">",
"     67",
"    </a>",
"    ]. Symptoms include lethargy, seizures, and dysarthria and are usually temporally related to postirradiation systemic methotrexate. In severe cases, symptoms can progress to ataxia, confusion, memory loss, dementia, and, rarely, death.",
"   </p>",
"   <p>",
"    A similar syndrome can occur in adults, whether or not chemotherapy is delivered at the same time as radiation. Delayed toxicity may be more common in patients with prolonged survival due to control of extracranial disease, particularly when whole brain RT has been combined with concurrent systemic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/68\">",
"     68",
"    </a>",
"    ]. Symptoms are similar to those found in children, although the onset may be delayed for years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The leukoencephalopathy may be associated with hydrocephalus in adults and children, and respond at least transiently to ventriculoperitoneal shunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Cerebral atrophy may become evident with additional follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114056057\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare late effect of radiation is a reversible syndrome characterized by migraine-like headaches often accompanied by focal neurologic signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures lasting days to weeks. The disorder called SMART (Strokelike Migraine Attacks after Radiation Therapy) may be associated with transient gadolinium enhancement of focal areas of the cortex and thus be confused with recurrent tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/72\">",
"     72",
"    </a>",
"    ]. The exact mechanism is unknown but cerebral vascular reactivity appears to be normal during the attack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neurocognitive effects in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating adverse effects of cranial irradiation upon neurocognitive function from the effects of the underlying malignancy can be very difficult. Within the last decade, prospective studies have been performed to characterize accurately the effects of cranial irradiation upon neurocognitive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/74\">",
"     74",
"    </a>",
"    ]. It is important for such studies to include long follow-up whenever feasible, because impaired neurocognitive function may become evident as a late effect of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/75\">",
"     75",
"    </a>",
"    ]. Important data on the impact of RT on neurocognitive function has been derived from studies in adults with brain metastases and low-grade gliomas, as well as in pediatric patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors may contribute to a deterioration in neurocognitive function in patients with brain metastases. In addition to cranial irradiation, these include disease progression, other treatments (surgery, chemotherapy) medications, and paraneoplastic syndromes.",
"   </p>",
"   <p>",
"    Several important observations were noted in a large trial of patients receiving WBRT for brain metastases with or without motexafin gadolinium, in which neurocognitive function was prospectively assessed in all patients at baseline and at multiple intervals until death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Over 90 percent of patients had evidence of neurocognitive function impairment at baseline, especially in the realms of fine motor control, executive function, and memory. The extent of impairment at baseline was correlated with the indicator lesion volume prior to treatment, and higher baseline neurocognitive function was associated with longer overall survival duration.",
"   </p>",
"   <p>",
"    A subsequent report on the 208 patients treated with WBRT alone analyzed the relationship between the response of metastases to WBRT and changes over time in neurocognitive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/77\">",
"     77",
"    </a>",
"    ]. The major findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A good response to WBRT, as assessed by tumor volume after treatment, was associated with improved neurocognitive function by all eight parameters analyzed in the 132 patients alive at two months.",
"     </li>",
"     <li>",
"      When neurocognitive function for the entire group was analyzed at four months, there was a significant decline in scores normalized to the patients' own baseline. This deterioration was due to the large number of patients with progressive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other important results were noted in the only randomized trial comparing surgical resection versus surgery plus WBRT in patients with a solitary brain metastasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/78\">",
"     78",
"    </a>",
"    ]. The rate of recurrence within the brain was significantly higher for patients who had surgery alone (70 versus 18 percent with surgery plus WBRT). Patients who received the combination were also significantly less likely to die of neurologic causes than patients who were treated with surgery alone.",
"   </p>",
"   <p>",
"    In contrast to these findings, a small randomized trial found that adding WBRT to stereotactic radiosurgery (SRS) increased the likelihood of a decline in learning and memory function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/79\">",
"     79",
"    </a>",
"    ]. A much larger randomized trial that will further examine this issue is being conducted by the North Central Cancer Treatment Group (NCT00377156) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'SRS plus WBRT versus SRS alone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, it seems likely that the major determinant of neurocognitive function in patients with brain metastases is the burden of disease in the brain and that a response to WBRT outweighs any deleterious effect from treatment, except for those few patients in whom one anticipates prolonged survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Low-grade glioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of cranial irradiation upon neurocognitive function in patients with low-grade glioma are particularly important since these patients often enjoy long survivorship. Effects in these patients may be due to either the tumor, RT, or antiepileptic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been one randomized study comparing immediate postoperative RT versus delayed RT given at the time of tumor progression. The time to neurological progression was delayed significantly by the use of immediate postoperative RT, although survival was unchanged. Seizures were better controlled in the group receiving early treatment. Unfortunately, neurocognitive function outcomes were not studied in detail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44568?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of low-grade glioma\", section on 'Timing of RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the observational study with the longest follow-up, 195 patients with low-grade glioma, including 104 who had received RT were compared with a control group of healthy individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an initial report at a mean of six years after initial treatment, the low-grade glioma patients had lower ability in all cognitive domains compared with controls. However, the use of RT was not associated with poorer cognitive function, except among patients who received a daily radiation dose greater than 2 Gy, where compromised memory was observed. In the same study, anticonvulsant medication was associated with a sixfold increase in risk of compromised capacity for perceptual tasks and in attention and executive function, effects that may be attributed to medications or seizures. Details concerning the total dose and volume treated in patients who received greater than 2 Gy per fraction were not provided, and there might have been unrecognized negative selection biases, since patients with more extensive disease might have been treated with higher doses per fraction in view of an expectation of a poorer prognosis.",
"     </li>",
"     <li>",
"      A subsequent study evaluated the effects of RT in a subset of 65 patients who were assessed for cognitive effects at a mean of 12 years after initial treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/84\">",
"       84",
"      </a>",
"      ]. All patients were considered clinically stable since their first assessment. RT had been part of the original treatment in 32 (49 percent). In all but two cases this had consisted of focal radiotherapy rather than whole brain RT, and in all but three cases, the fraction dose was &le;2 Gy. At the second assessment, patients who had received RT had significant impairment compared with patients who did not have RT as part of their original treatment in three cognitive domains: executive functioning, information processing speed, and attention. Detailed analyses suggested that these deficits could not be attributed exclusively to dose fraction or anticonvulsant usage, and that these deficits were at least in part attributable to RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One potential source of bias, however, is that patients who were treated with RT immediately after diagnosis were compared with patients who had survived without a recurrence. Patients not treated initially with RT who recurred prior to the second analysis were excluded from the comparison cohort. Thus, it is not possible to know the average degree of cognitive impairment in a population of patients with low grade glioma who were not treated with RT initially when potentially adverse effects of tumor recurrence are factored in.",
"   </p>",
"   <p>",
"    In a prospective study of 203 patients with low-grade glioma randomized to receive either a lower dose (50.4 Gy in 28 fractions) or a higher dose (64.8 Gy in 36 fractions) of post-operative RT, 5 percent of those without tumor progression were noted to have had deterioration of neurocognitive function five years after treatment, when assessed by the Folstein Mini-Mental State Examination (MMSE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/85\">",
"     85",
"    </a>",
"    ]. The MMSE has significant limitations for assessing neurocognitive function, particularly its lack of sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/86\">",
"     86",
"    </a>",
"    ]. However, deteriorations in this score are indicative of impairment.",
"   </p>",
"   <p>",
"    Taken together, these studies indicate that in adults with brain tumors, early cognitive dysfunction is the result of the tumor. However, in long-term survivors, radiation may cause some impairment, even when the RT is given focally and fraction size is limited.",
"   </p>",
"   <p>",
"    In addition, in any analysis of the late effects of cranial radiation upon neurocognitive function, the potential contributing effects of other anti-cancer treatments must be carefully weighed. For example, systemic chemotherapy may affect neurocognitive function, even in patients who have not received brain irradiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Prophylactic cranial irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic cranial irradiation (PCI) is established treatment for patients with small cell lung cancer and acute lymphoblastic leukemia and has been proposed to treat advanced non-small cell lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/87\">",
"     87",
"    </a>",
"    ]. In adults with small cell lung cancer, PCI substantially decreases the incidence of brain metastases and improves survival and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=see_link\">",
"     \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To what extent PCI causes cognitive dysfunction is still not established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/89\">",
"     89",
"    </a>",
"    ]. Many patients with small cell lung cancer have cognitive abnormalities prior to treatment. Patients are also treated with chemotherapeutic agents that may be neurotoxic. Some studies suggest that the effects of PCI on cognitive function, at least in adults, are minor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36446525\">",
"    <span class=\"h3\">",
"     Head and neck tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT for nasopharyngeal carcinomas may entail significant radiation doses to the temporal lobes. This has been associated with measurable deficits in cognitive function (short-term memory, language abilities) when patients pretreatment abilities are compared with those one year after treatment, and the extent of the deficit is related to the dose of radiation to the temporal lobe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/90\">",
"     90",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11587957\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several strategies to reduce the risk of neurocognitive decline after WBRT are under active investigation and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H1473216#H1473216\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Neuroprotective strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited clinical data have yielded conflicting results about the impact of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/91-93\">",
"     91-93",
"    </a>",
"    ] or the acetylcholinesterase inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/94\">",
"     94",
"    </a>",
"    ] on neurocognitive function, fatigue, and quality of life following cranial irradiation. The results are illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized double-blind trial evaluated 83 children who were long-term survivors of either acute lymphoblastic leukemia or malignant brain tumors and who had neurocognitive impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/92\">",
"       92",
"      </a>",
"      ]. The patients received a three-week crossover course of treatment with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      (0.3",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or placebo. Methylphenidate therapy was associated with improvements in attention and social deficits compared to placebo. No advantage was seen with higher doses of methylphenidate (0.6",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"     </li>",
"     <li>",
"      In a double-blind trial that was terminated prematurely, 68 patients with primary or metastatic brain tumors were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/93\">",
"       93",
"      </a>",
"      ]. Eight weeks after completion of RT, there was no difference in fatigue or cognition compared to placebo.",
"     </li>",
"     <li>",
"      In a phase II study, 24 patients with low-grade gliomas were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      for 24 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/94\">",
"       94",
"      </a>",
"      ]. Donepezil significantly improved several parameters of cognitive functioning (including attention, concentration, and verbal memory) and mood compared to baseline and the washout evaluation six weeks after completion of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results with both of these agents require further confirmation to establish their role in the treatment of patients who have neurocognitive dysfunction following cranial irradiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neurocognitive effects in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial irradiation in children warrants special attention in view of the potential for impairment of growth and development of the central nervous system. Although deficits may not be detected immediately after treatment, severe cognitive, social, and behavioral deficits can become evident years after the original diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13736?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the management of central nervous system tumors in children\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The toxicity of cranial irradiation in children has been studied in a variety of settings, with the highest doses being used in children treated for primary tumors of the central nervous system, somewhat lower doses used in children receiving PCI as part of their treatment for acute lymphoblastic leukemia, and much lower doses to the brain incidental to irradiation for hemangiomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Primary CNS tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher doses of radiation are often required in the treatment of primary CNS tumors, and late toxicity has been particularly prominent in young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. A retrospective series analyzed 194 children treated for primary brain malignancies before the age of three years at St. Jude's Research Hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/96\">",
"     96",
"    </a>",
"    ]. The most common tumor types included pilocytic astrocytoma, ependymoma, and medulloblastoma (43, 41, and 37 cases, respectively).",
"   </p>",
"   <p>",
"    In a longitudinal analysis of neurocognitive function in these children, craniospinal irradiation was associated with significantly greater progressive impairment of intelligence quotient (IQ) compared to local RT or treatment without radiation (-1.3 versus -0.5 versus +0.9 IQ points per year, respectively). Furthermore, craniospinal irradiation was associated with a significantly higher incidence of severe impairment (IQ &lt;70) than either local RT or treatment without RT (71 versus 24 versus 20 percent, respectively).",
"   </p>",
"   <p>",
"    Similar results were seen in a multicenter study of 111 children with medulloblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/97\">",
"     97",
"    </a>",
"    ]. Children at high risk (those with either metastatic disease or measurable residual tumor &ge;1.5 cm3) received craniospinal irradiation (36 to 39.6 Gy) and a conformal boost to the site of the primary tumor, while those at average risk received a lower dose of craniospinal irradiation (23 Gy), with boosts to the tumor bed and posterior fossa. The patients were evaluated for both IQ and academic achievement at baseline and one, two, and five years.",
"   </p>",
"   <p>",
"    Multivariate analysis revealed statistically significant declines in IQ (1.6",
"    <span class=\"nowrap\">",
"     points/year),",
"    </span>",
"    as well as in reading, spelling, and mathematics. The decline in these parameters was more pronounced in the high-risk group, which had received the higher dose of irradiation. However, the most important risk factor for impaired neurocognitive function was young age at the time of diagnosis; this was particularly evident for impairment of reading skills.",
"   </p>",
"   <p>",
"    The especially high risk of late RT effects in very young children with brain tumors prompted research into the use of chemotherapy to delay the use of RT in children diagnosed with brain tumors before the age of three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/99\">",
"     99",
"    </a>",
"    ]. However, this strategy is not advisable for all tumor types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific long-term follow-up guidelines for survivors of childhood CNS tumors have been published by the Children's Oncology Group and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    (accessed",
"    <span class=\"nowrap\">",
"     1/19/2010)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deficits in attention and performance have been observed in children and young adults receiving conformal RT for brain tumors. In a prospective series of 120 patients, long-lasting abnormalities were identified, which were attributed to a combination of local tumor effects, surgical intervention, and central nervous system irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Acute lymphoblastic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI has been associated with neurocognitive dysfunction in children being treated for acute lymphoblastic leukemia (ALL). This effect has been related to the dose of radiation. Modern PCI regimens typically are limited to a total dose of 18 Gy, a dose which appears to minimize such effects. The effects of PCI on neurocognitive function in children treated for ALL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'CNS preventive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hemangioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much lower doses of radiation are used for the treatment of cutaneous hemangiomas on the head, and these are associated with incidental radiation to the brain. In an epidemiologic study of individuals examined at age 18, those who received &gt;100 mGy were less likely to attend high school, independent of their socioeconomic status, compared to those who received less or no radiation. The damaging doses overlap with those imparted by brain CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25546?source=see_link&amp;anchor=H41#H41\">",
"     \"Management of infantile hemangiomas\", section on 'Other modalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cerebrovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occlusive vascular disease presenting with ischemic events and stroke has been reported as a late complication of cranial irradiation. Children are probably more susceptible to radiation-induced vasculopathy than adults, and the supraclinoid region of the internal carotid seems especially vulnerable. Receipt of chemotherapy may also contribute to risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. The reported median time from RT to clinical events is 40 to 60 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/104,106\">",
"     104,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of stroke following RT is significantly elevated in five-year survivors of both childhood leukemia and brain tumors. A report from the Childhood Cancer Survivor Study analyzed 4828 leukemia survivors, 1871 brain tumor survivors, and 3846 siblings of cancer survivors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/105\">",
"       105",
"      </a>",
"      ]. The relative risk (RR) of stroke among the leukemia survivors was 6.4 compared to siblings, while the RR for children with brain tumors was 29.0. Patients with leukemia or brain tumors who did not receive radiation also had an increased risk of stroke compared with the sibling comparison group. Thus other treatment modalities, such as chemotherapy or surgery, or the cancers themselves may be independently increasing the risk of stroke. The patients who received less than 30 Gy did not have a significantly increased risk of stroke compared with the patients who received no radiation at all. As a consequence, many pediatric radiation oncology protocols are attempting to lower the dose of radiation in various malignancies.",
"     </li>",
"     <li>",
"      An angiographic appearance similar to that seen in Moyamoya disease has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/106,107\">",
"       106,107",
"      </a>",
"      ]. In a review of 54 reported cases, 56 percent were in children younger than five years of age, 26 percent had neurofibromatosis type 1, and 69 percent had a low-grade glioma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/106\">",
"       106",
"      </a>",
"      ]. The median time from RT to onset of symptoms was 40 months. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=see_link\">",
"       \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation fields that include the circle of Willis appear to confer higher risk for neurovascular events than focal brain radiation to other areas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/104\">",
"       104",
"      </a>",
"      ]. In a single-center retrospective study of 431 pediatric brain tumor survivors, 62 percent received some form of brain radiation; the hazard ratio (HR) for stroke or TIA was highest in patients who received radiation to the circle of Willis (HR 9.0, 95 percent CI 1.2 &ndash; 70). In the adjusted model, only radiation to the circle of Willis (HR 4.35) and chemotherapy (HR 3.38) were significantly associated with stroke or TIA. Recurrent stroke or TIA occurred in five out of ten patients despite secondary stroke prevention measures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intracerebral cavernous malformations have been reported after cranial irradiation with a median latency of three to six years, and these may cause intracranial bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. The reported cumulative incidence in retrospective uncontrolled studies ranges from three to 43 percent at 10 years, with the range likely dependent in large part upon the sensitivity of the imaging technique. The study that reported the highest incidence included gradient echo sequences and defined cavernoma as the interval appearance of a lesion of any size demonstrating magnetic susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/110\">",
"     110",
"    </a>",
"    ]. As with other cerebrovascular complications, children appear to be at higher risk than adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/108,111\">",
"     108,111",
"    </a>",
"    ]. The risk of bleeding is not well studied but appears to be low; some lesions may enlarge over time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18584?source=see_link&amp;anchor=H13#H13\">",
"     \"Vascular malformations of the central nervous system\", section on 'Cavernous malformations'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Although RT to a large volume of the carotid arteries is uncommon during the treatment of intracranial tumors, it is common in the management of head and neck cancers and some other tumors that can involve lymph nodes in the neck, and may increase the risk of stroke in these patients. However, radiation fields that include the lower common carotid artery as part of treatment to supraclavicular or internal mammary lymph nodes for breast cancer have not been associated with an increased incidence of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H29#H29\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Radiotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822529#H3822529\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Carotid artery injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary stroke prevention measures, including antiplatelet therapy and treatment of other risk factors, have not been well-studied in this setting, but should be considered in individual patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7751?source=see_link\">",
"     \"Moyamoya disease: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Effects on the eyes and optic pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT may have a series of acute and delayed effects on the eyes and optic pathways. As an example, during treatment, radiation may stimulate the retinal photoreceptors, causing patients to perceive light sensations transiently immediately after radiation treatment to fields that include segments of the optic pathways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Cataracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced cataracts may result after low doses of radiation to the lens of the eye. Patients typically present with painless visual impairment two to eight years following radiation therapy. In a retrospective study of over 1000 patients who received total body irradiation for bone marrow transplant, either 10 Gy in one fraction or 12 Gy in conventional fractionation, 60 percent of the patients receiving one dose and 43 percent of the patients receiving fractionated radiation developed cataracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/113\">",
"     113",
"    </a>",
"    ]. Cataract development is strongly correlated with the chronic use of steroids in these patients. The treatment is the same as in non-radiation-induced cataracts, namely cataract removal and prosthetic lens placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuropathy typically presents with painless monocular or bilateral visual impairment developing over one to several weeks and beginning around 6 to 24 months after radiation. The incidence of mild, transient radiation effects on the optic nerves is not well reported. Fortunately, severe optic neuropathy after cranial irradiation is uncommon with doses less than 54 Gy to the optic chiasm and less than 59 Gy to an optic nerve. In one study, no injuries were seen in 106 optic nerves receiving less than 59 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fraction size greatly impacts the incidence of optic neuropathy, with larger fraction sizes associated with higher rates of neuropathy. In a study of 55 patients receiving 45 to 55 Gy for pituitary adenomas or craniopharyngiomas, 18 percent of patients receiving fraction sizes larger than 2.5 Gy developed optic neuropathy, while no patients receiving fraction sizes less than 2.5 Gy developed optic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/115\">",
"     115",
"    </a>",
"    ]. In the more severe cases of optic neuropathy, steroids are unlikely to provide benefit. Hyperbaric oxygen has provided limited success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/116\">",
"     116",
"    </a>",
"    ]. Anticoagulation is sometimes tried, with uncertain results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late onset of optic neuropathy has been reported in three cases of patients who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for glioblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/117\">",
"     117",
"    </a>",
"    ]. Assessment of this risk requires additional data from ongoing glioblastoma trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=see_link&amp;anchor=H15#H15\">",
"     \"Neurologic complications of cancer treatment with biologic agents\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optic neuropathy has been reported with lower doses of radiation as a complication of prophylactic chemotherapy plus cranial irradiation for acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Xerophthalmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xerophthalmia (dry eyes) can be a complication of radiation to the eye. This is generally mild and has been most frequently reported in patients treated for lymphoid malignancies of the orbit and ocular adnexa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. The incidence and severity varies with the radiation dose to the lacrimal gland as the rate of dry eyes increases with doses above 30 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal injury due to retinal ischemia can also occur after radiation. Radiation retinopathy is often asymptomatic and is found incidentally on fundoscopic exam. If symptomatic, it presents as painless loss of vision months to years after radiation. Risk factors for radiation retinopathy include radiation dose, prior chemotherapy, and diabetes. In one study of 64 patients receiving RT for head and neck tumors, 27 eyes in 26 patients developed symptomatic radiation retinopathy resulting in visual acuity of",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    or worse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/122\">",
"     122",
"    </a>",
"    ]. Fourteen of the injured eyes developed rubeosis iridis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neovascular glaucoma. No patient who received less than 45 Gy developed retinal complications, but the incidence of retinopathy increased with higher doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Cortical blindness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortical blindness has been reported after a combination of surgical resection, RT, and interleukin-2 for a patient with a brain metastasis of renal cell carcinoma in the left occipital cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/123\">",
"     123",
"    </a>",
"    ]. MR imaging disclosed signal abnormalities without mass effect in the white matter of the parietal and occipital lobes bilaterally, including the optic radiations.",
"   </p>",
"   <p>",
"    A more common cause of cortical blindness, not directly related to cranial radiation, is the reversible posterior leukoencephalopathy syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. This disorder is associated with drugs such as cyclosporin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , systemic hypertension, and sometimes seizures, which can occur during radiation therapy. The MRI shows bilateral hyperintensity in parietal and occipital lobes, similar to radiation necrosis, and the lesions are usually normal on diffusion-weighted images suggesting vasogenic edema. The syndrome is usually reversible and the patient usually makes a full recovery if the underlying cause is corrected (eg, if blood pressure is controlled or causal drugs are withdrawn). On rare occasions there is restricted diffusion, permanent MRI changes. Although the disorder usually affects posterior areas of the brain, it may be more widespread and involve the frontal lobes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Ototoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinnitus and high frequency hearing loss are acute effects that occasionally occur during cranial irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/21\">",
"     21",
"    </a>",
"    ]. These symptoms are often due to radiation-induced otitis media, causing mucosal vasodilatation and eustachian tube edema. Symptoms typically resolve spontaneously, but occasional patients need myringotomy for symptomatic relief.",
"   </p>",
"   <p>",
"    Hearing loss months to years after radiation is usually due to sensorineural damage that occurs in patients treated for head and neck cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/126-129\">",
"     126-129",
"    </a>",
"    ]. This was illustrated by a review of records from 325 patients treated for head and neck tumors between 1964 and 2000 at a single institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/126\">",
"     126",
"    </a>",
"    ]. Sensorineural hearing loss was observed in 15 percent of patients, and multivariate analysis showed that age and radiation dose to the cochlea were significant risk factors. For patients receiving doses over 60.5 Gy, the five-year risk of clinically overt hearing loss was 37 percent.",
"   </p>",
"   <p>",
"    Late sensorineural hearing loss also occurs in children who are treated with cranial irradiation for brain tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. In a study of 78 children who were assessed by audiometry and who had not received platinum-based chemotherapy, hearing loss was documented in 11 cases (14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/130\">",
"     130",
"    </a>",
"    ]. Ototoxicity was related to the dose of radiation to the cochlea. A cumulative cochlear dose less than 35 Gy was recommended for patients receiving a total tumor dose of 54 to 59.4 Gy in 30 to 33 fractions.",
"   </p>",
"   <p>",
"    Hearing loss can also occur with fractionated stereotactic radiotherapy or radiosurgery for vestibular schwannomas (acoustic neuromas). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Cisplatin chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    , which itself may cause hearing loss, results in synergistic ototoxicity with RT, especially in the high-frequency speech range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. In a randomized trial of 115 patients treated for nasopharyngeal carcinoma, hearing thresholds at 4 kHz were significantly worse for patients receiving combined modality therapy compared to those treated with radiation alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/133\">",
"     133",
"    </a>",
"    ]. Impairment began shortly after treatment and then stabilized after one year. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link&amp;anchor=H2#H2\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some reports suggest that up to 50 percent of long term survivors of medulloblastoma who have received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and RT require hearing aids, although the incidence may be lower with modern radiation techniques that spare key structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/134\">",
"     134",
"    </a>",
"    ]. Cochlear implantation can be considered in patients with complete deafness after RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of patients with advanced head and neck cancers may include RT to cranial nerve VIII or the cochlea in some cases. In this setting, the ototoxicity of combined treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and RT is significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. This was illustrated by a randomized trial in which patients were randomly assigned to cisplatin administered either intraarterially or intravenously, and RT was given to a total dose of 70 Gy in 35 fractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/136\">",
"     136",
"    </a>",
"    ]. Both regimens induced significant hearing loss, which was worse at higher frequencies. More ears required hearing aids after intravenous cisplatin (72 of 148 [49 percent] versus 51 of 143 [36 percent], with intraarterial chemotherapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Endocrinopathies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Hypothalamus and pituitary gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothalamic and pituitary endocrinopathies occur commonly in both children and adults following RT that includes these structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/96,138-146\">",
"     96,138-146",
"    </a>",
"    ]. Such injury may occur after doses as low as 20 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time course of endocrine dysfunction is variable, with patients typically having abnormal serum hormone levels long before clinical symptoms develop. As a result, monitoring patients who are at risk for radiation-induced hormone deficiencies may be warranted.",
"   </p>",
"   <p>",
"    If symptoms occur, the manifestations depend upon the specific hormone deficiency. (See appropriate topic reviews on the different hormone deficiencies).",
"   </p>",
"   <p>",
"    The time course of hypopituitarism was illustrated in a longitudinal study of 47 patients treated with RT for acromegaly in which progressive hypopituitarism was observed in 78 percent at ten years and in 85 percent at 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/146\">",
"     146",
"    </a>",
"    ]. In another series of 107 patients treated to the base of skull primarily for extraneural tumors (primarily chordomas and chondrosarcomas), the rates of hyperprolactinemia, hypothyroidism, hypogonadism, and hypoadrenalism at 10 years were 84, 63, 36, and 28 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/145\">",
"     145",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children treated with RT for nonpituitary-related primary brain tumors, irradiation of the pituitary hypothalamic axis can result in delayed growth hormone (GH), adrenocorticotrophic hormone (ACTH), and thyroid-stimulation hormone (TSH) deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=see_link&amp;anchor=H25#H25\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\", section on 'Endocrine abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with acute lymphoblastic leukemia (ALL), cranial RT is now generally restricted to high-risk disease. However, there are many adult survivors who were treated during childhood with cranial RT, which may result in delayed deficiency of GH secretion. In a retrospective study of ALL survivors at a mean of 25 years after the original diagnosis, insufficient or deficient GH secretion was more common in those who had received cranial RT (41 of 48 patients [85 percent] versus 5 of 24 patients [21 percent] among those who had not received cranial RT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/147\">",
"     147",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1833?source=see_link\">",
"     \"Growth hormone deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children with brain tumors or leukemia who receive craniospinal irradiation, a significant proportion develop hypothyroidism. This may be a manifestation of either central hypothyroidism, due to irradiation of the pituitary through the cranial fields, or primary hypothyroidism due to irradiation of the thyroid from the spinal field. As the radiation dose to the thyroid after craniospinal irradiation is relatively low, primary hypothyroidism is often transient and does not require life-long thyroid replacement. A more detailed review of the delayed effects of radiation on thyroid function is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link&amp;anchor=H12#H12\">",
"     \"Acquired hypothyroidism in childhood and adolescence\", section on 'Craniospinal irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Radiation-induced tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following cranial irradiation, there is an increased risk of secondary meningiomas, malignant gliomas, and nerve sheath tumors; the risk of meningiomas and gliomas is proportional to the dose of cranial irradiation. The evidence linking these secondary brain tumors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=see_link&amp;anchor=H8#H8\">",
"     \"Risk factors for brain tumors\", section on 'Radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=see_link&amp;anchor=H627075214#H627075214\">",
"     \"Meningioma: Epidemiology, risk factors, and pathology\", section on 'Ionizing radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second malignancies that occur in young children treated with cranial or craniospinal irradiation are not limited to tumors arising within the brain. This is illustrated by a Pediatric Oncology Group study, in which 198 children less than three years of age were treated for a brain tumor with irradiation and chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/22/37226/abstract/148\">",
"     148",
"    </a>",
"    ]. In this group, five developed second primary malignancies, with an interval from diagnosis of initial tumor to second malignancy ranging from 33 to 92 months. Second malignancies included myelodysplastic syndrome (two children), acute myeloid leukemia (one child), a sarcoma, and a meningioma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=see_link\">",
"       \"Patient information: Hair loss from cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cranial radiation is an integral component of the management of patients with primary and metastatic brain tumors and certain types of leukemia. However, cranial radiation is associated with risks of various acute and late toxicities, and these risks should be acknowledged and discussed during the pretreatment counseling session with any patient for whom cranial radiation is recommended. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cranial radiation can have deleterious effects on the vasculature of the brain as well as on glial cells and their precursors. Inflammation and blood-brain barrier disruption may also contribute to cellular damage. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute effects of radiation are those that occur during the course of treatment. Some of the more common adverse effects include transient worsening of baseline neurological symptoms due to cerebral edema, nausea and vomiting, dermatitis, and alopecia. Acute encephalopathy, conductive hearing loss, mild myelosuppression, mucositis and parotitis may also occur. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early-delayed reactions that may occur several months after brain radiation include increased contrast enhancement on MRI, somnolence, and transient worsening of focal neurological symptoms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Early-delayed reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late reactions, defined as those occurring more than 90 days after the start of cranial irradiation, are more varied and generally less reversible than early or early-delayed reactions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Late reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation necrosis is a serious complication that typically develops one to three years after radiation. Symptoms produced by localized brain necrosis depend upon the location of the lesion and can include focal neurologic deficits or more generalized signs and symptoms of increased intracranial pressure. The risk increases with higher doses per fraction. Management is primarily symptomatic. Small studies have suggested that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      may improve clinical and radiographic outcomes, but larger studies are needed to better define its role in the treatment of symptomatic brain radiation necrosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiation necrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both focal brain radiation and whole brain radiation have been associated with a decline in neurocognitive function over time in some patients that can be difficult to differentiate from the effects of the tumor itself, other therapies such as surgery and chemotherapy, and concomitant medications such as anticonvulsants. Data regarding the neurocognitive effects of brain radiation derive primary from adults with brain metastases or low-grade gliomas and children with primary brain tumors or leukemia. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Neurocognitive effects in adults'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Neurocognitive effects in children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain radiation has been associated with a variety of cerebrovascular complications, including occlusive vascular disease resembling Moyamoya, ischemic stroke, and intracerebral cavernous malformations that may cause intracranial bleeding. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Cerebrovascular effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional well-described late complications of cranial irradiation include cataracts, optic neuropathy, xerophthalmia, retinopathy, ototoxicity, and endocrinopathies. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Effects on the eyes and optic pathways'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Ototoxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38\">",
"       'Endocrinopathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following cranial irradiation, there is an increased risk of secondary meningiomas, malignant gliomas, and nerve sheath tumors. Survivors of childhood cranial or craniospinal radiation are at increased risk for intracranial tumors as well as myeloid neoplasms. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Radiation-induced tumors'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/1\">",
"      Hosking FJ, Feldman D, Bruchim R, et al. Search for inherited susceptibility to radiation-associated meningioma by genomewide SNP linkage disequilibrium mapping. Br J Cancer 2011; 104:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/2\">",
"      Rosenstein BS. Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics 2011; 12:267.",
"     </a>",
"    </li>",
"    <li>",
"     RTOG Acute Radiation Morbidity Scoring Criteria www.rtog.org/members/toxicity/acute.html (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/4\">",
"      Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/5\">",
"      Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/6\">",
"      Belka C, Budach W, Kortmann RD, Bamberg M. Radiation induced CNS toxicity--molecular and cellular mechanisms. Br J Cancer 2001; 85:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/7\">",
"      Rola R, Raber J, Rizk A, et al. Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol 2004; 188:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/8\">",
"      Nordal RA, Wong CS. Molecular targets in radiation-induced blood-brain barrier disruption. Int J Radiat Oncol Biol Phys 2005; 62:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/9\">",
"      Humpl T, Br&uuml;hl K, Bohl J, et al. Cerebral haemorrhage in long-term survivors of childhood acute lymphoblastic leukaemia. Eur J Pediatr 1997; 156:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/10\">",
"      Kurita H, Kawahara N, Asai A, et al. Radiation-induced apoptosis of oligodendrocytes in the adult rat brain. Neurol Res 2001; 23:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/11\">",
"      Hellstr&ouml;m NA, Bj&ouml;rk-Eriksson T, Blomgren K, Kuhn HG. Differential recovery of neural stem cells in the subventricular zone and dentate gyrus after ionizing radiation. Stem Cells 2009; 27:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/12\">",
"      Jaganathan A, Tiwari M, Phansekar R, et al. Intensity-modulated radiation to spare neural stem cells in brain tumors: a computational platform for evaluation of physical and biological dose metrics. J Cancer Res Ther 2011; 7:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/13\">",
"      Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010; 76:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/14\">",
"      Young DF, Posner JB, Chu F, Nisce L. Rapid-course radiation therapy of cerebral metastases: results and complications. Cancer 1974; 34:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/15\">",
"      Hindo WA, DeTrana FA 3rd, Lee MS, Hendrickson FR. Large dose increment irradiation in treatment of cerebral metastases. Cancer 1970; 26:138.",
"     </a>",
"    </li>",
"    <li>",
"     Phillips P, Delattre JY, Berger C. Early and progressive increases in regional brain capillary permeability following single and fractionated dose cranial radiation in the rat. Neurology1987; 37:301 (Abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/17\">",
"      Evans ML, Graham MM, Mahler PA, Rasey JS. Use of steroids to suppress vascular response to radiation. Int J Radiat Oncol Biol Phys 1987; 13:563.",
"     </a>",
"    </li>",
"    <li>",
"     DeAngelis LM, Posner JB. Neurologic Complications of Cancer, 2nd, Oxford University Press, 2008. p.163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/19\">",
"      Lawenda BD, Gagne HM, Gierga DP, et al. Permanent alopecia after cranial irradiation: dose-response relationship. Int J Radiat Oncol Biol Phys 2004; 60:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/20\">",
"      Aguiar D, Pazo R, Dur&aacute;n I, et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004; 66:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/21\">",
"      Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R. Radiotherapy-induced ear toxicity. Cancer Treat Rev 2003; 29:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/22\">",
"      Cairncross JG, Salmon J, Kim JH, Posner JB. Acute parotitis and hyperamylasemia following whole-brain radiation therapy. Ann Neurol 1980; 7:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/23\">",
"      Powell C, Guerrero D, Sardell S, et al. Somnolence syndrome in patients receiving radical radiotherapy for primary brain tumours: a prospective study. Radiother Oncol 2011; 100:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/24\">",
"      Breitbart W, Alici Y. Psychostimulants for cancer-related fatigue. J Natl Compr Canc Netw 2010; 8:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/25\">",
"      Ryan J. Radiation somnolence syndrome. J Pediatr Oncol Nurs 2000; 17:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/26\">",
"      Freeman JE, Johnston PG, Voke JM. Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukaemia. Br Med J 1973; 4:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/27\">",
"      Berg RA, Ch'ien LT, Lancaster W, et al. Neuropsychological sequelae of postradiation somnolence syndrome. J Dev Behav Pediatr 1983; 4:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/28\">",
"      Mandell LR, Walker RW, Steinherz P, Fuks Z. Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study. Cancer 1989; 63:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/29\">",
"      Uzal D, Ozyar E, Hayran M, et al. Reduced incidence of the somnolence syndrome after prophylactic cranial irradiation in children with acute lymphoblastic leukemia. Radiother Oncol 1998; 48:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/30\">",
"      Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995; 31:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/31\">",
"      Xu JL, Li YL, Lian JM, et al. Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging. Neuroradiology 2010; 52:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/32\">",
"      Armstrong C, Ruffer J, Corn B, et al. Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: neuropsychologic outcome and proposed mechanisms. J Clin Oncol 1995; 13:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/33\">",
"      Armstrong CL, Corn BW, Ruffer JE, et al. Radiotherapeutic effects on brain function: double dissociation of memory systems. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13:101.",
"     </a>",
"    </li>",
"    <li>",
"     RTOG Late Radiation Morbidity Scoring Schema www.rtog.org/members/toxicity/late.html (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     Burger P, Boydo OB. Radiation injury to the nervous system. In: The pathology of central nervous system radiation injury, Raven Press, New York  p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/36\">",
"      Burger PC, Mahley MS Jr, Dudka L, Vogel FS. The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases. Cancer 1979; 44:1256.",
"     </a>",
"    </li>",
"    <li>",
"     Leibel S, Sheline G. Tolerance of the brain and spinal cord to conventional therapeutic irradiation. In: Radiation Injury to the Nervous System, Gutin P, Leibel S, Sheline G (Eds), Raven Press, New York 1991. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/38\">",
"      Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/39\">",
"      Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006; 65:499.",
"     </a>",
"    </li>",
"    <li>",
"     Wara WM, Bauman GS, Sneed PK, et al. Brain, brain stem and cerebellum. In: Principles and Practice of Radiation Oncology, 3rd, Perez E, Brady LW (Eds), Lippincott-Raven, Philadelphia 1997. p.799.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/41\">",
"      Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000; 21:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/42\">",
"      Valk PE, Budinger TF, Levin VA, et al. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988; 69:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/43\">",
"      Thiel A, Pietrzyk U, Sturm V, et al. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. Neurosurgery 2000; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/44\">",
"      Barker FG 2nd, Chang SM, Valk PE, et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997; 79:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/45\">",
"      Doyle WK, Budinger TF, Valk PE, et al. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987; 11:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/46\">",
"      Janus TJ, Kim EE, Tilbury R, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993; 33:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/47\">",
"      Glantz MJ, Hoffman JM, Coleman RE, et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 1991; 29:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/48\">",
"      Ross DA, Sandler HM, Balter JM, et al. Imaging changes after stereotactic radiosurgery of primary and secondary malignant brain tumors. J Neurooncol 2002; 56:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/49\">",
"      Schwartz RB, Holman BL, Polak JF, et al. Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy. J Neurosurg 1998; 89:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/50\">",
"      Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2004; 54:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/51\">",
"      Quan D, Hackney DB, Pruitt AA, et al. Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. Neurology 1999; 53:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/52\">",
"      Davidson A, Tait DM, Payne GS, et al. Magnetic resonance spectroscopy in the evaluation of neurotoxicity following cranial irradiation for childhood cancer. Br J Radiol 2000; 73:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/53\">",
"      Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 2000; 21:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/54\">",
"      Lin A, Bluml S, Mamelak AN. Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neurooncol 1999; 45:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/55\">",
"      Kimura T, Sako K, Tanaka K, et al. Evaluation of the response of metastatic brain tumors to stereotactic radiosurgery by proton magnetic resonance spectroscopy, 201TlCl single-photon emission computerized tomography, and gadolinium-enhanced magnetic resonance imaging. J Neurosurg 2004; 100:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/56\">",
"      Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007; 67:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/57\">",
"      Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009; 94:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/58\">",
"      Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 2009; 75:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/59\">",
"      Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011; 79:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/60\">",
"      Furuse M, Kawabata S, Kuroiwa T, Miyatake S. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 2011; 102:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/61\">",
"      Jeyaretna DS, Curry WT Jr, Batchelor TT, et al. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 2011; 29:e159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/62\">",
"      Glantz MJ, Burger PC, Friedman AH, et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994; 44:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/63\">",
"      Chuba PJ, Aronin P, Bhambhani K, et al. Hyperbaric oxygen therapy for radiation-induced brain injury in children. Cancer 1997; 80:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/64\">",
"      Cihan YB, Uzun G, Yildiz S, D&ouml;nmez H. Hyperbaric oxygen therapy for radiation-induced brain necrosis in a patient with primary central nervous system lymphoma. J Surg Oncol 2009; 100:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/65\">",
"      Schellart NA, Reits D, van der Kleij AJ, Stalpers LJ. Hyperbaric oxygen treatment improved neurophysiologic performance in brain tumor patients after neurosurgery and radiotherapy: a preliminary report. Cancer 2011; 117:3434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/66\">",
"      Constine LS, Konski A, Ekholm S, et al. Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys 1988; 15:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/67\">",
"      Price RA, Jamieson PA. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 1975; 35:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/68\">",
"      Doyle DM, Einhorn LH. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys 2008; 70:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/69\">",
"      Frytak S, Shaw JN, O'Neill BP, et al. Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 1989; 12:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/70\">",
"      Tekk&ouml;k IH, Carter DA, Robinson MG, Brinker R. Reversal of CNS-prophylaxis-related leukoencephalopathy after CSF shunting: case histories of identical twins. Childs Nerv Syst 1996; 12:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/71\">",
"      Perrini P, Scollato A, Cioffi F, et al. Radiation leukoencephalopathy associated with moderate hydrocephalus: intracranial pressure monitoring and results of ventriculoperitoneal shunting. Neurol Sci 2002; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/72\">",
"      Kerklaan JP, Lycklama &aacute; Nijeholt GJ, Wiggenraad RG, et al. SMART syndrome: a late reversible complication after radiation therapy for brain tumours. J Neurol 2011; 258:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/73\">",
"      Farid K, Meissner WG, Samier-Foubert A, et al. Normal cerebrovascular reactivity in Stroke-like Migraine Attacks after Radiation Therapy syndrome. Clin Nucl Med 2010; 35:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/74\">",
"      Regine WF, Schmitt FA, Scott CB, et al. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys 2004; 58:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/75\">",
"      Duffey P, Chari G, Cartlidge NE, Shaw PJ. Progressive deterioration of intellect and motor function occurring several decades after cranial irradiation. A new facet in the clinical spectrum of radiation encephalopathy. Arch Neurol 1996; 53:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/76\">",
"      Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004; 22:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/77\">",
"      Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007; 25:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/78\">",
"      Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/79\">",
"      Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 10:1037.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on February 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/81\">",
"      Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol 2007; 81:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/82\">",
"      Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002; 52:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/83\">",
"      Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002; 360:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/84\">",
"      Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009; 8:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/85\">",
"      Brown PD, Buckner JC, O'Fallon JR, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 2003; 21:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/86\">",
"      Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 2003; 21:3557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/87\">",
"      Stuschke M, P&ouml;ttgen C. Prophylactic cranial irradiation as a component of intensified initial treatment of locally advanced non-small cell lung cancer. Lung Cancer 2003; 42 Suppl 1:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/88\">",
"      Tai TH, Yu E, Dickof P, et al. Prophylactic cranial irradiation revisited: cost-effectiveness and quality of life in small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/89\">",
"      Kanard A, Frytak S, Jatoi A. Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management. J Support Oncol 2004; 2:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/90\">",
"      Hsiao KY, Yeh SA, Chang CC, et al. Cognitive function before and after intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2010; 77:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/91\">",
"      Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998; 16:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/92\">",
"      Mulhern RK, Khan RB, Kaplan S, et al. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 2004; 22:4795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/93\">",
"      Butler JM Jr, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007; 69:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/94\">",
"      Shaw EG, Rosdhal R, D'Agostino RB Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006; 24:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/95\">",
"      Aarsen FK, Paquier PF, Reddingius RE, et al. Functional outcome after low-grade astrocytoma treatment in childhood. Cancer 2006; 106:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/96\">",
"      Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005; 23:7152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/97\">",
"      Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005; 23:5511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/98\">",
"      Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 1998; 16:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/99\">",
"      Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993; 328:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/100\">",
"      Duffner PK, Cohen ME, Sanford RA, et al. Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group. Med Pediatr Oncol 1995; 25:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/101\">",
"      Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/102\">",
"      Kiehna EN, Mulhern RK, Li C, et al. Changes in attentional performance of children and young adults with localized primary brain tumors after conformal radiation therapy. J Clin Oncol 2006; 24:5283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/103\">",
"      Hall P, Adami HO, Trichopoulos D, et al. Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ 2004; 328:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/104\">",
"      Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke 2012; 43:3035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/105\">",
"      Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006; 24:5277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/106\">",
"      Desai SS, Paulino AC, Mai WY, Teh BS. Radiation-induced moyamoya syndrome. Int J Radiat Oncol Biol Phys 2006; 65:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/107\">",
"      Ullrich NJ, Robertson R, Kinnamon DD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 2007; 68:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/108\">",
"      Strenger V, Sovinz P, Lackner H, et al. Intracerebral cavernous hemangioma after cranial irradiation in childhood. Incidence and risk factors. Strahlenther Onkol 2008; 184:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/109\">",
"      Burn S, Gunny R, Phipps K, et al. Incidence of cavernoma development in children after radiotherapy for brain tumors. J Neurosurg 2007; 106:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/110\">",
"      Lew SM, Morgan JN, Psaty E, et al. Cumulative incidence of radiation-induced cavernomas in long-term survivors of medulloblastoma. J Neurosurg 2006; 104:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/111\">",
"      Heckl S, Aschoff A, Kunze S. Radiation-induced cavernous hemangiomas of the brain: a late effect predominantly in children. Cancer 2002; 94:3285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/112\">",
"      Hooning MJ, Dorresteijn LD, Aleman BM, et al. Decreased risk of stroke among 10-year survivors of breast cancer. J Clin Oncol 2006; 24:5388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/113\">",
"      van Kempen-Harteveld ML, Struikmans H, Kal HB, et al. Cataract after total body irradiation and bone marrow transplantation: degree of visual impairment. Int J Radiat Oncol Biol Phys 2002; 52:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/114\">",
"      Parsons JT, Bova FJ, Fitzgerald CR, et al. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/115\">",
"      Harris JR, Levene MB. Visual complications following irradiation for pituitary adenomas and craniopharyngiomas. Radiology 1976; 120:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/116\">",
"      Borruat FX, Schatz NJ, Glaser JS, et al. Visual recovery from radiation-induced optic neuropathy. The role of hyperbaric oxygen therapy. J Clin Neuroophthalmol 1993; 13:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/117\">",
"      Kelly PJ, Dinkin MJ, Drappatz J, et al. Unexpected late radiation neurotoxicity following bevacizumab use: a case series. J Neurooncol 2011; 102:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/118\">",
"      Fishman ML, Bean SC, Cogan DG. Optic atrophy following prophylactic chemotherapy and cranial radiation for acute lymphocytic leukemia. Am J Ophthalmol 1976; 82:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/119\">",
"      De Cicco L, Cella L, Liuzzi R, et al. Radiation therapy in primary orbital lymphoma: a single institution retrospective analysis. Radiat Oncol 2009; 4:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/120\">",
"      Kennerdell JS, Flores NE, Hartsock RJ. Low-dose radiotherapy for lymphoid lesions of the orbit and ocular adnexa. Ophthal Plast Reconstr Surg 1999; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/121\">",
"      Bessell EM, Henk JM, Wright JE, Whitelocke RA. Orbital and conjunctival lymphoma treatment and prognosis. Radiother Oncol 1988; 13:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/122\">",
"      Parsons JT, Bova FJ, Fitzgerald CR, et al. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/123\">",
"      Pomeranz HD, Henson JW, Lessell S. Radiation-associated cerebral blindness. Am J Ophthalmol 1998; 126:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/124\">",
"      Kahana A, Rowley HA, Weinstein JM. Cortical blindness: clinical and radiologic findings in reversible posterior leukoencephalopathy syndrome: case report and review of the literature. Ophthalmology 2005; 112:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/125\">",
"      V&aacute;zquez E, Lucaya J, Castellote A, et al. Neuroimaging in pediatric leukemia and lymphoma: differential diagnosis. Radiographics 2002; 22:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/126\">",
"      Bhandare N, Antonelli PJ, Morris CG, et al. Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 2007; 67:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/127\">",
"      Ho WK, Wei WI, Kwong DL, et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Head Neck 1999; 21:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/128\">",
"      Herrmann F, D&ouml;rr W, M&uuml;ller R, Herrmann T. A prospective study on radiation-induced changes in hearing function. Int J Radiat Oncol Biol Phys 2006; 65:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/129\">",
"      Pan CC, Eisbruch A, Lee JS, et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2005; 61:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/130\">",
"      Hua C, Bass JK, Khan R, et al. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys 2008; 72:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/131\">",
"      Paulino AC, Lobo M, Teh BS, et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys 2010; 78:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/132\">",
"      Kretschmar CS, Warren MP, Lavally BL, et al. Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol 1990; 8:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/133\">",
"      Low WK, Toh ST, Wee J, et al. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 2006; 24:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/134\">",
"      Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002; 52:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/135\">",
"      Formanek M, Czerny C, Gstoettner W, Kornfehl J. Cochlear implantation as a successful rehabilitation for radiation-induced deafness. Eur Arch Otorhinolaryngol 1998; 255:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/136\">",
"      Zuur CL, Simis YJ, Lansdaal PE, et al. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 2007; 25:3759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/137\">",
"      Zuur CL, Simis YJ, Lansdaal PE, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys 2007; 68:1320.",
"     </a>",
"    </li>",
"    <li>",
"     Wara W, Bauman G, Sneed P. Brain, brain stem, and cerebellum. In: Principles and Practice of Radiation Oncology, Perez C, Brady L (Eds), Lippincott-Raven, Philadelphia 1998. p.777.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/139\">",
"      Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/140\">",
"      Taphoorn MJ, Heimans JJ, van der Veen EA, Karim AB. Endocrine functions in long-term survivors of low-grade supratentorial glioma treated with radiation therapy. J Neurooncol 1995; 25:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/141\">",
"      Clarson CL, Del Maestro RF. Growth failure after treatment of pediatric brain tumors. Pediatrics 1999; 103:E37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/142\">",
"      Collet-Solberg PF, Sernyak H, Satin-Smith M, et al. Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma. Clin Endocrinol (Oxf) 1997; 47:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/143\">",
"      Arlt W, Hove U, M&uuml;ller B, et al. Frequent and frequently overlooked: treatment-induced endocrine dysfunction in adult long-term survivors of primary brain tumors. Neurology 1997; 49:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/144\">",
"      Lam KS, Tse VK, Wang C, et al. Effects of cranial irradiation on hypothalamic-pituitary function--a 5-year longitudinal study in patients with nasopharyngeal carcinoma. Q J Med 1991; 78:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/145\">",
"      Pai HH, Thornton A, Katznelson L, et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001; 49:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/146\">",
"      Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005; 62:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/147\">",
"      Gurney JG, Ness KK, Sibley SD, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006; 107:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/22/37226/abstract/148\">",
"      Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 1998; 44:313.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7053 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37226=[""].join("\n");
var outline_f36_22_37226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiation dermatitis and alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hearing problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Myelosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mucositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114056038\">",
"      Parotitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EARLY-DELAYED REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MRI contrast enhancement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Somnolence and the somnolence syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Transient focal neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LATE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiation necrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diffuse white matter injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114056057\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neurocognitive effects in adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Low-grade glioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Prophylactic cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36446525\">",
"      - Head and neck tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11587957\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neurocognitive effects in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Primary CNS tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cerebrovascular effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Effects on the eyes and optic pathways",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Cataracts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Xerophthalmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Retinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Cortical blindness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Cisplatin chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Endocrinopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Hypothalamus and pituitary gland",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Radiation-induced tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7053|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/32/24075\" title=\"table 1\">",
"      RTOG acute morbidity crit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/0/9227\" title=\"table 2\">",
"      RTOG late morbidity crit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2566?source=related_link\">",
"      Complications of cranial stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=related_link\">",
"      Complications of spinal cord irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1833?source=related_link\">",
"      Growth hormone deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44568?source=related_link\">",
"      Management of low-grade glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=related_link\">",
"      Meningioma: Epidemiology, risk factors, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7751?source=related_link\">",
"      Moyamoya disease: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=related_link\">",
"      Neurologic complications of cancer treatment with biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13736?source=related_link\">",
"      Overview of the management of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3847?source=related_link\">",
"      Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_22_37227="Etiology infectious arthritis";
var content_f36_22_37227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of infectious arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical clues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        Healthy adults, skin breakdown, previously damaged joint (eg, rheumatoid arthritis), prosthetic joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strepotococcal species",
"       </td>",
"       <td>",
"        Healthy adults, splenic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neisseria gonorrhea",
"       </td>",
"       <td>",
"        Healthy adults (particularly young, sexually active), associated tenosynovitis, vesicular pustules, late complement deficiency, negative synovial fluid culture and gram stain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerobic gram negative bacteria",
"       </td>",
"       <td>",
"        Immune compromised hosts, gastrointestinal infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaerobic gram negative bacteria",
"       </td>",
"       <td>",
"        Immune compromised hosts, gastrointestinal infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterial species",
"       </td>",
"       <td>",
"        Immune compromised hosts, recent travel to or residence in an endemic area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal species (sporotrichosis, cryptococcus, blastomycosis, coccidioidomycosis)",
"       </td>",
"       <td>",
"        Immune compromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spirochete (Borellia burgdorferi)",
"       </td>",
"       <td>",
"        Exposure to ticks, antecedent rash, knee joint involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycoplasma hominis",
"       </td>",
"       <td>",
"        Immune compromised hosts with prior urinary tract manipulation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37227=[""].join("\n");
var outline_f36_22_37227=null;
var title_f36_22_37228="Treatment of Whipples disease";
var content_f36_22_37228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial therapy in Whipple's disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Initial therapy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        General infection",
"       </td>",
"       <td>",
"        <p>",
"         Ceftriaxone 2 g IV once daily",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        Penicillin G 2 million units IV every four hours",
"       </td>",
"       <td>",
"        Two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endocarditis",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin G 2 million units IV every four hours",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        Ceftriaxone 2 g IV once daily",
"       </td>",
"       <td>",
"        Four weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CNS disease",
"       </td>",
"       <td>",
"        <p>",
"         Ceftriaxone 2 g IV once daily",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        Penicillin G 4 million units IV every four hours",
"       </td>",
"       <td>",
"        Four weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If ceftriaxone and penicillin allergic",
"       </td>",
"       <td>",
"        <p>",
"         Trimethoprim-sulfamethoxazole one DS tablet three times daily",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        Streptomycin 1 g IM daily",
"       </td>",
"       <td>",
"        Two to four weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Maintenance therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All infections",
"       </td>",
"       <td>",
"        Trimethoprim-sulfamethoxazole one DS tablet twice daily",
"       </td>",
"       <td>",
"        One year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If sulfa allergic",
"       </td>",
"       <td>",
"        <p>",
"         Doxycycline 100 mg PO twice daily",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        Hydroxychloroquine 200 mg PO thrice daily",
"       </td>",
"       <td>",
"        One year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Therapy for relapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Initial therapy*",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin G 4 million units IV every 4 hours",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        Ceftriaxone 2 g IV twice daily",
"       </td>",
"       <td>",
"        Four weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maintenance therapy",
"       </td>",
"       <td>",
"        <p>",
"         Doxycycline 100 mg PO twice daily",
"         <strong>",
"          PLUS",
"         </strong>",
"         hydroxychloroquine 200 mg PO thrice daily",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        Trimethoprim-sulfamethoxazole one DS tablet twice daily for 1 year",
"       </td>",
"       <td>",
"        One year",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Initial therapy must be followed by maintenance therapy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37228=[""].join("\n");
var outline_f36_22_37228=null;
var title_f36_22_37229="Results bilateral LVRS in NETT";
var content_f36_22_37229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of bilateral LVRS compared to medical therapy in patients with severe emphysema.",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        90-day mortality",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        P-value",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total mortality",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Risk ratio*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        P-value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        LVRS",
"       </td>",
"       <td class=\"subtitle2\">",
"        Medical therapy",
"       </td>",
"       <td class=\"subtitle2\">",
"        LVRS",
"       </td>",
"       <td class=\"subtitle2\">",
"        Medical therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group A",
"       </td>",
"       <td>",
"        20/70 (28.6)",
"       </td>",
"       <td>",
"        0/70 (0)",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"       <td>",
"        42/70",
"       </td>",
"       <td>",
"        30/70",
"       </td>",
"       <td>",
"        1.82",
"       </td>",
"       <td colspan=\"2\">",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group B",
"       </td>",
"       <td>",
"        4/139 (2.9)",
"       </td>",
"       <td>",
"        5/151 (3.3)",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        26/139",
"       </td>",
"       <td>",
"        51/151",
"       </td>",
"       <td>",
"        0.47",
"       </td>",
"       <td colspan=\"2\">",
"        0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group C",
"       </td>",
"       <td>",
"        6/206 (2.9)",
"       </td>",
"       <td>",
"        2/213 (0.9)",
"       </td>",
"       <td>",
"        0.17",
"       </td>",
"       <td>",
"        34/206",
"       </td>",
"       <td>",
"        39/213",
"       </td>",
"       <td>",
"        0.98",
"       </td>",
"       <td colspan=\"2\">",
"        0.70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group D",
"       </td>",
"       <td>",
"        7/84 (8.3)",
"       </td>",
"       <td>",
"        0/65 (0)",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        28/84",
"       </td>",
"       <td>",
"        26/65",
"       </td>",
"       <td>",
"        0.81",
"       </td>",
"       <td colspan=\"2\">",
"        0.49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group E",
"       </td>",
"       <td>",
"        11/109 (10.1)",
"       </td>",
"       <td>",
"        1/111 (0.9)",
"       </td>",
"       <td>",
"        0.003",
"       </td>",
"       <td>",
"        27/109",
"       </td>",
"       <td>",
"        14/111",
"       </td>",
"       <td>",
"        2.06",
"       </td>",
"       <td colspan=\"2\">",
"        0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"9\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Improvement in exercise capacity",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Improvement in health-related quality of life",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        LVRS",
"       </td>",
"       <td class=\"subtitle2\">",
"        Medical therapy",
"       </td>",
"       <td class=\"subtitle2\">",
"        Odds ratio",
"       </td>",
"       <td class=\"subtitle2\">",
"        P-value",
"       </td>",
"       <td class=\"subtitle2\">",
"        LVRS",
"       </td>",
"       <td class=\"subtitle2\">",
"        Medical therapy",
"       </td>",
"       <td class=\"subtitle2\">",
"        Odds ratio",
"       </td>",
"       <td class=\"subtitle2\">",
"        P-value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group A",
"       </td>",
"       <td>",
"        4/58 (7)",
"       </td>",
"       <td>",
"        1/48 (2)",
"       </td>",
"       <td>",
"        3.48",
"       </td>",
"       <td>",
"        0.37",
"       </td>",
"       <td>",
"        6/58 (10)",
"       </td>",
"       <td>",
"        0/48 (0)",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group B",
"       </td>",
"       <td>",
"        25/84 (30)",
"       </td>",
"       <td>",
"        0/92 (0)",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"       <td>",
"        40/84 (48)",
"       </td>",
"       <td>",
"        9/92 (10)",
"       </td>",
"       <td>",
"        8.38",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group C",
"       </td>",
"       <td>",
"        17/115 (15)",
"       </td>",
"       <td>",
"        4/138 (3)",
"       </td>",
"       <td>",
"        5.81",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"       <td>",
"        47/115 (41)",
"       </td>",
"       <td>",
"        15/138 (11)",
"       </td>",
"       <td>",
"        5.67",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group D",
"       </td>",
"       <td>",
"        6/49 (12)",
"       </td>",
"       <td>",
"        3/41 (7)",
"       </td>",
"       <td>",
"        1.77",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        18/49 (37)",
"       </td>",
"       <td>",
"        3/41 (7)",
"       </td>",
"       <td>",
"        7.35",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group E",
"       </td>",
"       <td>",
"        2/65 (3)",
"       </td>",
"       <td>",
"        2/59 (3)",
"       </td>",
"       <td>",
"        0.90",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        10/65 (15)",
"       </td>",
"       <td>",
"        7/59 (12)",
"       </td>",
"       <td>",
"        1.35",
"       </td>",
"       <td>",
"        0.61",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Groups A-E are defined in the text.",
"    <br>",
"     Values in parentheses indicate percentage.",
"     <div class=\"footnotes\">",
"      LVRS: lung volume reduction surgery.",
"      <br>",
"       * Risk ratio for total mortality in surgically versus medically treated patients during a mean follow-up of 29.2 months.",
"       <br>",
"        &bull; Increase in the maximal workload of more than 10W from the patient's postrehabilitation base-line value (24 months after randomization).",
"        <br>",
"         &Delta; Improvement in the health-related quality of life was defined as a decrease in the score on the St. George's Respiratory Questionnaire of more than 8 points (on a 100-point scale) from the patient's postrehabilitation baseline score (24 months after randomization).",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"      Adapted with permission from: Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26:167. Copyright &copy; 2005 Thieme Medical Publishers, Inc.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37229=[""].join("\n");
var outline_f36_22_37229=null;
var title_f36_22_37230="CDC algorithm for screening for GBS in preterm labor";
var content_f36_22_37230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    CDC algorithm for screening for GBS in preterm labor before 37 weeks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 372px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CDC: Centers for Disease Control and Prevention; GBS: Group B streptococcus.",
"     <br>",
"      * If patient has undergone vaginal-rectal GBS culture within the preceding 5 weeks, the results of that culture should guide management. GBS-colonized women should receive intrapartum antibiotic prophylaxis. No antibiotics are indicated for GBS prophylaxis if a vaginal-rectal screen within 5 weeks was negative.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Patient should be regularly assessed for progression to true labor; if the patient is considered not to be in true labor, discontinue GBS prophylaxis.",
"       <br>",
"        &Delta; If GBS culture results become available prior to delivery and are negative, then discontinue GBS prophylaxis.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Unless subsequent GBS culture prior to delivery is positive.",
"         <br>",
"          &sect; A negative GBS screen is considered valid for 5 weeks. If a patient with a history of PTL is re-admitted with signs and symptoms of preterm labor and had a negative GBS screen &gt;5 weeks prior, she should be rescreened and managed according to this algorithm at that time.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010. MMWR 2010; 59:No. RR-10.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37230=[""].join("\n");
var outline_f36_22_37230=null;
var title_f36_22_37231="Subdural hematoma in an infant with mortality";
var content_f36_22_37231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Subdural hematomas with mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An infant presented in coma with pupillary dilatation. There was no significant trauma history. Computed tomography (Figure A) reveals a large right, concave subdural hematoma and significant brain shift. After urgent craniotomy, the patient had malignant brain swelling due to the underlying traumatic and hypoxic-ischemic injury on follow up computed tomography (Figure B), and did not survive. Bilateral retinal hemorrhages and skeletal fractures were also detected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_22_37231=[""].join("\n");
var outline_f36_22_37231=null;
               